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Abstract 
The effectiveness of exogenous cellular therapies has been limited by the ability to efficiently 
and locally deliver cells to a region of interest. We have developed biological sutures, formed from fibrin 
microthreads, to overcome these delivery issues and demonstrated increased cell engraftment 
compared to the current gold standard. However, the cell seeding efficiency onto the sutures is low and 
during implantation cells are subjected to shear forces as the sutures are pulled through the tissue. As a 
result, cells go unused after seeding and an uneven distribution of cells from the entry point to exit of 
the suture. By adding cell attachment and adhesion promoters and increasing culture time we proposed 
to overcome these issues. We have developed a shear loading method to evaluate the changes in 
cellular adhesion. Either poly-l-lysine or vitronectin was used to coat sutures. Uncoated control and 
coated sutures were then seeded with 100,000 human mesenchymal stem cells (hMSCs) for 24hrs or 
control sutures were seeded for 48hrs. An in vitro shear stress model was created by spinning seeded 
sutures with a centrifuge. Cell number per unit length prior to and post spinning were compared. To 
compare the effect of modifications on cell morphology cells were qualitatively assessed and nuclear 
alignment was evaluated as a robust measurement for overall cellular angle. Control sutures were found 
to have 6,821±739cells/cm prior to spinning, while sutures modified with poly-l-lysine resulted in 
4,226±1,003cells/cm and vitronectin had 19,604±1,829cells/cm (p<0.05 vs. control and poly-l-lysine). 
48hrs seeding resulted in a cell number to 4,417±2,266 cells/cm. Spinning resulted in relative decreases 
in cell number for control and coated sutures. Cells remained attached after sutures were spun after 
increased incubation time. Cells aligned along the long axis of individual microthreads; the alignment on 
control sutures was significantly different from all modifications. There was no difference in alignment 
between modifications, although they were significantly different compared to cells grown on 
topographically flat tissue culture plastic. These results demonstrated increased cell seeding efficiency 
and cell number for vitronectin coated biological sutures and increased cell adhesion following 
increased incubation time. The combination of these two modifications may lead to increased quantity 
and more evenly distributed cells delivered to diseased tissues by increasing initial cell number, 
increasing cell engraftment, and increased resistance to shear. 
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Chapter 1: Introduction  
As our understanding of tissue engineering principles grows, the potential for use of cellular 
therapies to treat previously incurable pathologies becomes closer to reality. One particularly relevant 
target for cellular therapy is the necrotic area of the heart post infarct. A major hurdle remaining in the 
application of these therapies are limitations imposed by current inefficient and poorly-localized cell 
delivery techniques.1 For these treatments to become viable there needs to be an effective and efficient 
mode of delivery developed.  
The heart pumps blood throughout the body, driving the exchange of oxygen and carbon 
dioxide and delivering essential nutrients to organs. The efficiency of this pump is essential to life. 
Decreased blood flow causes a decrease in overall bodily functions. When the vasculature of the heart 
narrows or is blocked, an area of heart muscle is starved of blood and the necessary oxygen, resulting in 
a myocardial infarction. The area of ischemic cardiac myocytes will eventually perish and that area will 
become non-contractile scar tissue reducing overall cardiac output.2 
The heart has limited regenerative ability. Research has shown that the cardiac myocyte 
proliferation rate is about 1% per year.3 Even after an increase in proliferation post infarct, it is not 
enough to effectively regenerate the infarct area.4 Current pharmacological treatments following a 
myocardial infarction only treat the symptoms, such as angina, or attempt to prevent further 
infarctions.5 Surgical techniques attempt to revascularize or correct the ventricular shape change 
following ventricular remodeling. 6,7 Yet, there is no clinical treatment to restore the functional 
contractile cardiomyocytes that once inhabited the non-contractile scar tissue. 
Cellular therapy has been proposed as a way to regenerate the myocardium. Delivery of cells to 
the infarct area have shown the ability to revascularize, reduce wall thinning and infarct size and restore 
regional and global mechanical function of the heart.8 Many different cells types have been used in 
cellular therapy including skeletal myoblasts, embryonic derived cardiomyocytes, hematopoietic stem 
cells, cardiac stem cells, embryonic stem cells and mesenchymal stem cells.9–11 To deliver cells to the 
infarct area, surgeons and researchers have adapted known techniques such as intravenous injection, 
angioplasty and direct injections. Using these technologies results in low cellular engraftment rates due 
to a of lack targeted and efficient delivery.1 
Based on prior work, fibrin microthread sutures were developed to overcome the problems of 
delivery localization and efficiency associated with current delivery methods.12 Fibrin microthread 
sutures can be seeded with viable human mesenchymal stem cells (hMSCs) and maintain their 
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multipotency.13 Sutures can then be delivered to the beating myocardium. As compared to the current 
gold standard of direct myocardium injection, fibrin microthread sutures were shown to have a higher 
engraftment rate (12% vs. 64%, respectively). hMSCs were found throughout the suture tract and 
localized with the native cardiomyocytes unlike other methods where transplanted cells create islands 
and can be distributed throughout the body.14–17 
Fibrin microthread sutures have shown the ability to efficiently deliver cells to specific regions of 
the target tissue; however there are drawbacks to this system. After implantation, it was observed that 
more cells engrafted at the entry point of the suture as compared to the exit point. This is believed to be 
a result of shear stresses that cells are subjected to during implantation. Another concern relates to the 
efficiency of loading hMSCs onto the sutures which is low (≈12%), resulting in about 88% of cells going 
unused.  
We propose two strategies to increase cell attachment, loading efficiency, and cellular adhesion 
to the fibrin microthread sutures. The first strategy will coat the sutures with commonly used cellular 
adhesion and attachment promoters in an attempt to increase cellular binding domains on the biological 
sutures. The second will increase the incubation time of cells on the biological sutures increasing the cell 
to scaffold contact duration. All sutures will be qualitatively and quantitatively assessed for cell 
attachment. To evaluate the cellular adhesion of hMSCs onto the sutures we will develop an in vitro 
assay and quantify cell number.  
We were able to increase cellular attachment, loading efficiency and adhesion through coating 
sutures and increasing the seeding time. By increasing the cell loading efficiency, cell number, and the 
cellular adhesion on the sutures we hope to increase the delivery of cells to areas of diseased tissue and 
restore the function of these tissues.  
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Chapter 2: Background 
Cellular therapies have been developed and show promise to restoring diseased tissue to 
normal function. Unfortunately these therapies lack methods to effectively and efficiently deliver cells to 
the area of diseased tissue. Prior work in our lab has shown that human mesenchymal stem cells 
(hMSCs) can be seeded onto fibrin microthread sutures and that these cells can then be efficiently 
delivered to a specific region of interest, in particular through the heart wall. 13,15 This method has been 
shown more effective than the current gold standard however as the method is still novel, further 
characterization and improvements can be made to the sutures.15  
2.1: Cellular Therapy  
Some pathologies can leave patients with permanent scars, disfigurement, or a lifelong 
treatment plan that addresses symptoms rather than the underlying prognoses. This results in a 
decrease in quality of life, and in the most severe cases these pathologies can result in death. Advances 
in the field of biomedical research over the past quarter century have created a source for new 
groundbreaking treatments for pathologies that are currently untreatable. Particular advances in cellular 
therapy and regenerative medicine have shown promise and have been deemed the “medicine for the 
21st century”.  Regenerative medicine and cellular therapy is a multidisciplinary approach for the repair, 
replacement, or regeneration of damaged or diseased tissue.18,19 The field as a whole is in its infancy, as 
demonstrated by the limited clinically available procedures. Researchers have looked to the use of 
pharmaceuticals, growth factors, gene therapy, scaffolds, delivery of cells (primary, embryonic stem 
cells, adult stem cells, and induced pluripotent stem cells), or any combination of the prior options to 
improve damaged tissue.8,20–22  The final outcomes often result in improvements in the function of 
damaged or diseased tissues or organs, but frequently the duration and improvement of function is 
limited. Some researchers have begun to tailor their treatments to specific pathologies, increasing the 
number of applications and the effectiveness of cellular therapy.     
2.1.1: Applications for Cellular Therapy 
 Cellular therapy has shown promise for repairing, replacing, and regenerating diseased or 
damaged tissue. Examples of this can be found in many tissues and organ systems including bone 
marrow, cancerous tumors,  cartilage, and the heart.23–25 
 One of the first success stories in cellular therapy is hematopoietic cell transplant for patients 
suffering from blood diseases such as lymphoma and leukemia.23 This procedure utilizes chemotherapy 
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to destroy malfunctioning hematopoietic stem cells in the patient’s bone marrow and then an allograft 
of hematopoietic stem cells is intra-arterially injected into the patient. This procedure has greatly 
increased the survival rate for patients but suffers from a low effective engraftment rate of stem cells 
into the voided areas, reducing efficacy, and like all allogeneic transplants it risks the chance of immune 
rejection.26  
Cell therapies are also being developed as a less-destructive alternative to other conventional 
cancer treatments including chemotherapy, radiation therapy and systemic pharmaceuticals. It was 
shown that hMSCs have the ability to migrate and engraft into the connective tissue stroma of tumors.25 
Utilizing this ability, researchers have used genetically modified hMSCs as a delivery vector for antitumor 
agents to treat cancers.25,27 These modified cells are introduced with an intra-venous injection and 
allowed to home to the tumor, though effectiveness is hampered by low engraftment rates inside of the 
tumors due to the lack of targeted delivery.25  
More recently the clinically approved cell therapy Carticel® developed by Genzyme™ Corp, 
hopes to regenerate damaged hyaline cartilage in the knee. This technique utilizes autologous 
chondrocytes expanded in vitro and then delivered back the damaged area.24 In order to keep the cells 
contained to the damaged area the cells are injected under a periosteal patch.28 This technique has 
shown early and mid-term repair; however, debate continues regarding long term outcomes. Issues 
surrounding this procedure include the need for two surgeries, donor site morbidity, de-differentiation 
of chondrocytes in culture, and the need to contain the cells with a surgical patch. 28,29 
Therapies designed to regenerate contractile tissue following a myocardial infarction have 
entered clinical trials.11,30,31 Stem cells are harvested from the patient and then delivered in and around 
the infarct area in an attempt to regenerate the myocardium. This technique has showed promise yet 
issues with the inefficient cellular delivery mechanisms have arisen.1,17,32    
2.1.2: Cardiac Regeneration 
 The leading cause of death in the United States is cardiovascular disease, for example 7.9 
million Americans currently suffer from a myocardial infarction, a form of coronary heart disease.33 Five 
years after a patient suffers from their first myocardial infarction 28% of men and 41% of women will be 
diagnosed with heart failure and of those patient diagnosed with heart failure the five year survival rate 
is 50%.33  The annual cost of coronary heart disease and myocardial infarction in the United States is 
estimated to be over $56 billion.33 There is no cure for coronary heart disease and myocardial infarctions 
creating the demand for new therapies to combat the disease.  
 14 
 
The Heart and Myocardial Infarction 
The heart is the main pump that delivers oxygen and nutrient rich blood throughout the body. 
The heart has its own coronary circulation system that provides the myocytes with enough oxygen and 
nutrients to continually pump blood throughout the body and satisfy the resting and active metabolic 
rate. If a portion of the coronary circulation is occluded, an area of the heart and the corresponding 
myocytes are starved (Figure 1). When the myocytes are starved of oxygen and glucose their typical 
aerobic production of adenosine triphosphate (ATP) is slowed or stopped. If the occlusion persists the 
ischemic cells turn to anaerobic glycolysis. Decreases in the intracellular pH of myocytes due to 
byproduct buildup results in edema and ultimately cell death.34 Further damage such as wall thinning 
and ventricular dilatation is a result of the inflammatory response.2 This area of necrotic tissue will soon 
become a scar after the infiltration of collagen depositing fibroblasts. After a myocardial infarction 
healthy, compliant, and contractile tissue becomes  fibrous, stiff, and  non-contractile scar tissue.2   
The heart serves as the electromechanical pump for the circulatory system, delivering oxygen 
and nutrient rich blood to the body. If the heart were to suffer from damage the efficiency of delivering 
blood would diminish and could ultimately lead to death as the bodies major organs suffer from 
ischemia. The heart lacks the ability to effectively regenerate after injury and current interventions do 
not fix the actual problem. Developing a method for cardiac regeneration could have a huge clinical 
impact. 
 
 
Figure 1: Blockage or narrowing of a coronary artery causing ischemia which results in an infarct.
35
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Myocardial Remodeling and Current Treatments 
After an infarction in the left ventricle, the heart begins to compensate for the loss of contractile 
function with short and long term changes in anatomy and physiology. As a short term solution to 
preserve the overall cardiac output the sarcomere length of cardiomyocytes of non-infarcted 
myocardium changes and heart rate increases.2 Long term compensation after scar formation results in 
myocyte hypertrophy and alterations in the ventricular architecture.2,36 The response of myocyte 
hypertrophy and change in ventricular shape, causes the heart to work harder to pump the same 
amount of blood consequently the heart’s ability to efficiency pump blood throughout the body 
decreases.  
Current clinical treatments for myocardial infarction usually result in pharmaceutical or surgical 
intervention but they only treat the effects or symptoms of an infarction. The prescription of 
pharmaceutics only treats the symptoms of an infarct, such as angina, or attempt to prevent further 
infarctions.5  Surgeons typically use two types of procedures, a bypass surgery to restore blood flow or 
the restoration of the elliptical shape through removal of the infarct and direct linear closure or 
synthetic patch implantation both are highly invasive. Coronary artery bypass grafting (CABG) restores 
the coronary blood flow to the infarct, in an attempt to revascularize the area.7 Surgical restoration of 
the ventricular shape has demonstrated its effectiveness in clinical trials.37 These are complex surgical 
procedures that requires an arrested heart, removal of the necrotic tissue and the direct closure of heart 
wall or the replacement with a synthetic polymer patch in an attempt to restore the size and elliptical 
shape of the heart.6 Restoration of the optimal dimensions is difficult because the direct closure or 
placement of the biomaterial patch is not always perfect.38,39 Endocardial patch plasty is usually done in 
conjunction with CABG to restore blood flow to the epicardial layer of the heart wall.7 The purpose of 
these procedures is to prevent further changes in shape, volume, and wall thinning that could lead to 
rupture.38,39 After these clinical treatments heart function still remains compromised as the overall 
problem of loss of contractile tissue has not been addressed. 
Myocardial Cellular Therapy        
 Conventional surgical options do not regenerate lost cells and the overall function of the heart 
remains compromised. A potential solution may lie in the limited ability of the heart to regenerate over 
time, though this innate capacity alone is not enough to overcome the loss of cells post infarct.3,4 
Recently researchers have focused on the leveraging this capacity for cellular therapy for the 
regeneration of myocardium and restoration of mechanical function. Two potential routes for the 
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regeneration of myocardium are currently studied; endogenous therapies and exogenous cellular 
delivery.  
Endogenous therapy utilizes the recruitment of the patients own cells to regenerate the 
myocardium. Recent data suggest that cardiomyocytes possess the ability to proliferate around the 
infarct border zone, the mechanisms of which are highly debated.3,4 This has spurred researchers to 
develop ways in which to use this proliferative ability and regenerate the myocardium. Under specific 
conditions they have shown ways to induce myocyte proliferation and increase mechanical 
function.9,20,40 In order for endogenous therapy to be effective in regenerating the myocardium, the cells 
must home to or migrate into the dead tissue. This proves to be a difficult as the ischemic environment 
of the infarct is not conducive to cell viability. As a result cells accumulate around the border zone of the 
infarct and do not actually infiltrate or regenerate the necrotic tissue.41     
Exogenous cellular therapies or cellular cardiomyoplasty employ the delivery of autologous or 
allogeneic cells to the infarct region. A variety of cell types have been used to regenerate myocardium 
post infarct including skeletal myoblasts, blood derived progenitor cells, bone marrow derived 
mesenchymal stem cells, embryonic stem cells, cardiac stem cells, and induced pluripotent stem cells. In 
addition, some stem cell types (mesenchymal stem cells, embryonic stem cells, cardiac stem cells and 
induced pluripotent stem cells) have been shown to differentiate with measured degrees of expression 
towards a cardiac lineage. The technologies currently being used as delivery mechanisms are inefficient 
and lack localized delivery. Examples of current methods being used include intravenous injection (IV), 
intracoronary injection (IC), intramuscular injection (IM), and cell-seeded scaffolds and biomaterial 
patches.     Despite inefficiencies, addition of these cells to the infarct area have shown a reduction in 
infarct size, increase in wall thickness and increase in mechanical function.10,30,42–48  
 
2.1.3: Current Cardiac Cell Delivery Methods  
For exogenous cell therapy to reach therapeutic levels there needs to be an effective mode of 
delivery. The technologies currently used are inefficient and lack localized delivery. To overcome these 
obstacles researchers deliver large cell numbers, ultimately wasting 85-99% of the cells. Not only is 
there a waste of cells but also increases the cost and time of the procedure. Fibrin microthread 
biological sutures have been proposed as a way to efficiently and locally deliver stem cells to the 
myocardium.   
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Intravenous injection is a minimally invasive delivery technique where a cell suspension is 
injected into the patient via a peripheral vein. Cells then travel systemically and must home to and 
migrate into the injured myocardium. This method is highly inefficient and lacks localized delivery and 
results in an engraftment rate of 1%.17,32 Likely due do to cells traveling systemically, most cells are 
caught in the lungs and the filtering organs.17,32,49   
Intracoronary injection (IC) delivery utilizes the technology of the commonly performed 
angioplasty procedure. A catheter is placed in the coronary artery upstream from the infarct and an 
angioplasty balloon is inflated. A cell suspension is injected behind the balloon. The blood flow is 
occluded allowing for the engraftment of cells. IC delivery is able to target the infarct yet only 3-6% of 
cell engraft.32,50 Most cells are washed away when the coronary artery is reperfused. Cell type and size 
must be taken into consideration when performing this technique. In order to engraft, cells must 
migrate through the vascular wall. So they must possess the ability for transendothelial migration. Also, 
if the cell is too large it could lead to capillary occlusion causing micro-infarction and an increase in the 
infarct size.1    
Another method to target the infarct is through the use of cell seeded scaffolds, or material 
based patches. These patches are surgically attached to the ventricle wall over the infarct area. This 
technique has a 1% engraftment rate. This is the result of poor cell viability because scaffolds lack a 
vascular network. Cells also have difficulty migrating through the material and into the myocardium.51  
The current gold standard with the highest engraftment rate is direct intramuscular (IM) 
injection of cells into the myocardium and the infarct area (also known as intramyocardial injection). 
This procedure can be done during an open-surgical revascularization surgery or a less invasive catheter 
transepicardial approach. 1,52,53 IM injection has the highest engraftment rates and possesses the ability 
to locally deliver cells to the infarct region. However, only 3-14% of cells are retained in the region of 
interest mainly due to extravasation after needle retraction, lack of a solid matrix for cell adhesion, and 
damage to cells after being injected through a small gage hypodermic needle.45,50,54,55 IM injection 
engraftment rate  has increased with a co-injection of a gel matrix, pro-survival drugs and/or growth 
factor cocktails.10,45,56,57 IM injections can target a specific region although concerns exist due to the 
nature of needle punctures and injection.58 After injection cells engraft in islet like clusters that could 
then induce harmful arrhythmia.1,16 
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2.2: Fibrin Microthread Biological Sutures 
2.2.1: Fibrin Scaffolds 
 Recent biomaterials research has revealed the potential utility of naturally-derived fibrin as a 
biomaterial. Under native circumstances, fibrin exists as a provisional biopolymer matrix that aids 
healing by providing binding motifs allowing attachment and migration of cells.59 Fibrin is created 
through the interaction of the free circulating blood protein fibrinogen and thrombin, which is created 
at a wound site.59 More specifically, when combined thrombin polymerizes fibrinogen into the insoluble 
protein fibrin that halts bleeding and promotes healing.59–61 It naturally contains arginine-glycine-
aspartic acid (RGD) ligand binding motifs allowing for cell adhesion, can be produced from autologous 
fibrinogen and thrombin, is angiogenic, and is FDA approved for clinical use as sealants and glues.56,62,63 
 Recently, researchers have turned to fibrin gels and 3D scaffolds as a way to locally deliver cells 
to the infarct zone. They have shown increased retention of cells compared to gold standard of 
intramyocardial injection.57,64 Cells in fibrin gels injected into the myocardium suffer the same fate as 
cells injected in saline or culture medium, as most of the gel is ejected out of the needle track before 
polymerization because of heart contractions.57,65  3D scaffolds and gels suffer from problems such as 
poor cell viability and gel extravasation. Often times scaffold are upwards of 2-4 mm thick and cells that 
have been seeded inside the avascular scaffolds are starved due to the limited depth of nutrient and 
oxygen diffusion (≈150µm).8,57,66 Of further concern, unpolymerized components or pieces of the gel 
could cause further complications due to circulatory occlusion in patients.     
2.2.2: Fibrin Microthread Biological Sutures  
 Recently Cornwell et al. developed and evaluated discrete fibrin microthreads, a novel scaffold 
for tissue regeneration which provides cells with attachment sites, promotes migration, controls cell 
orientation, provides cell signaling and can incorporate growth factors.12,21 Discrete fibrin microthreads 
can further be grouped together to create a rope or bundle like construct. Proulx et al. demonstrated 
that fibrin microthread bundles could be seeded with and effectively support hMSCs, a clinically relevant 
cell type used for cardiac regeneration. Research indicates bundled fibrin microthreads supported hMSC 
viability, proliferation, and preserves their multipotency.13  
Further work with fibrin microthreads by Guyette et al. showed that a suture needle could be 
fixed onto a microthread bundle construct, creating a fibrin microthread biological suture. Guyette et al. 
was then able to seed these sutures and deliver the hMSC seeded sutures to the myocardium in a rat 
model. Their study compared biological suture delivery and intramuscular injection and resulted in a 
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63.6 ± 10.6% and 11.8 ± 6.2% engraftment rate respectively (Figure 2). Further histological analysis 
showed that hMSCs delivered with the sutures were only found in and around the suture track and 
localized with the native myocardium.15 
   
  
 
Figure 2: Biological sutures deliver more cells into the myocardium (left) the results in higher cell engraftment rate (right) 
when compared to intramyocardial injection. Brackets indicate statistical difference, unpaired, two-tail, unequal variance t 
tests for two groups p<0.05.
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2.2.3: Limitations of Fibrin Microthread Sutures 
Fibrin microthread biological sutures have been shown to successfully deliver stem cells locally 
and efficiently to the heart as compared to the gold standard.  But the efficiency of loading hMSCs onto 
the sutures is low (≈12%), for example, to deliver 5,000 cells per cm to the heart, approximately 50,000 
cells will need to be seeded per cm of suture. To increase the effectiveness of fibrin microthread 
biological sutures as a delivery mode, not only do more cells need to attach but they must also remain 
attached to the sutures throughout implantation. After histological assessment, it was observed that 
more cells tended to engraft at the entry point of the suture as compared to the exit point (Figure 3). It 
is believed that this non-uniform distribution stems from shear stresses encountered in pulling the 
suture through tissue. When cells have not fully attached or the shear force overcomes the adherence 
strength of the cells, the cells will detach. A method to strengthen the cellular adhesion and efficiency of 
loading cells onto the sutures must be developed.  
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Figure 3: Mean cell distribution (± SEM) throughout the area of cell engrafted myocardium after biological suture 
implantation (blue) compared to intramuscular (IM) injection (red). Sample size for biological suture and IM injection was 5 
and 4, respectively. Brackets indicate statistical difference, one-way ANOVA with Tukey post-hoc p<0.05. Significant drop at 
50% of the biological suture implantation was due to surgical error when a suture was driven through the myocardium and 
into the ventricular cavity.
15
 
2.3: Cellular Attachment and Alignment  
Research has shown that the geometric and microenvironmental surroundings play a direct role 
in cellular behavior.67 Biochemical, mechanical, and topological cues can direct the adhesion, 
proliferation, migration, differentiation, and apoptosis of a cell.68 A cell’s response to a particular surface 
can be seen through overall changes in size, shape, and orientation. Cells have been shown to align and 
elongate along the long axis of cylindrical substrates similar to fibrin microthreads.69,70  Achieving a 
proper attachment and alignment relationship between cells and their delivery substrate is a critical 
precursor to successful delivery, integration, and therapeutic restoration of function. 
2.3.1: Cellular Attachment   
Cellular adhesion to the scaffold is a crucial first step in tissue engineering and regenerative 
medicine. In order to tailor the attributes of surfaces and tissue engineering scaffolds researchers have 
often turned to the use of cellular attachment and adhesion promoters including extracellular matrix 
(ECM) proteins and charge enhancers.  How a cell reacts to a surface is directly related to the interaction 
of the cells binding receptors (integrins) and the surfaces adhesion sites (ligands).61 How and what 
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integrin binds, has shown to play a direct role in the cellular behavior, affecting adhesion, cell growth, 
differentiation, gene expression and migration.61,71–77 
Cellular Attachment and Adhesion Promoters 
In improving cellular adhesion to a biomaterial it can be advantageous to provide cellular 
attachment and adhesion promoters to a surface upon which they would not naturally exist. Materials 
used to increase cellular attachment and adhesion includes ECM proteins such as fibronectin, vitronectin 
and collagen, and charge enhancers such as poly-l-lysine. 75  
In vivo fibrin clots interact with ECM proteins fibronectin and vitronectin to create a provisional 
matrix for cellular adhesion and migration during wound healing.59,78,79 These proteins have been shown 
to bind to fibrin and present similar binding domains such as the arginine-glycine-aspartic (RGD) acid 
sequence and increase the attachment of hMSCs on substrates as compared to other ECM proteins.73,75–
77 Vitronectin similarly to fibronectin has a dynamic interaction with fibrin that naturally occurs in the 
body and efficient binds to fibrin clots.80 Vitronectin has two binding locations for fibrin and neither 
involves the RGD sequence (see Error! Reference source not found.). This allows the ligand to always be 
present for cell anchorage. hMSCs possess integrins that bind to the RGD sequence and specific ligands 
associated with vitronectin.59,81–83 The synthetic amino acid chain poly-l-lysine acts as a charge enhancer 
and is commonly used to increase cell attachment.75,84 By coating the surface of the microthread sutures 
with poly-l-lysine it would alter the surface change of fibrin and its interactions with serum proteins in 
the media, the cell membrane, and overall cell binding.75,84,85 
Manipulating Seeding Conditions  
Dynamic seeding and extended culture times are tools used by researchers to increase cell 
number and attachment onto tissue engineered scaffolds. Rotational and dynamic seeding allows the 
scaffold to be completely covered with cells and has shown increased cell attachment when compared 
to static seeding.86–88 By rotating or agitating the cell suspension it increases the interaction and contact 
time with the scaffold or in our case the sutures. Increasing the seeding time or the cell concentration is 
another way to increase the contact and interaction of the cells with the scaffold. Prior work in our lab 
has shown increased incubation time on statically seeded fibrin microthread bundles results in an 
increase in cell number.13 We have also shown that by rotating the cell suspension and the sutures we 
can increase the initial cell attachment as compared to static seeding after 24 hours.14 A combination of 
these two methods could result in further cell attachment and an increase in cell number on our 
biological sutures. 
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2.3.2: Cellular Alignment 
 The biological and mechanical function of an organ can often be dictated by the tissues 
microarchitecture and cellular alignment. For example in tendons and ligaments, cells and the 
extracellular matrix fibers align in the long axis of the tendon or ligament in the direction of tension. 
Skeletal muscle is formed from myoblasts that create highly aligned muscle fibers. The direction of the 
fiber is essential to the generation of contractile force. Cardiomyocytes and the fibroblasts contained in 
the extracellular matrix of the heart have a complex organization that is critical to electrical propagation 
and mechanical contraction.89 This alignment produces the efficient twisting motion that pumps blood 
throughout the body. The heart is a highly aligned organ, when delivering cells to the heart it is 
important to match this alignment. Delivery of aligned cells could aid in the electrical and mechanical 
coupling and integration into the tissue, preventing the arrhythmias that occur when implanting 
unorganized and unaligned cells.16  
Results found in literature with cylindrical and grooved substrates similar to fibrin microthread 
bundles and sutures show the alignment of cells.12,21,69,70,89,90 Alignment of cells occurs physiologically. 
The ability of fibrin microthreads to induce alignment will be important because it simulates 
physiological architectures. This can be seen in work done by Page et al. who suggest that the 
architecture and alignment capabilities of fibrin microthreads were some of the contributing factors to 
the regeneration of skeletal muscle defects.22 Alignment is integral to the current and further success of 
fibrin microthreads as a scaffold for tissue regeneration and engineering. 
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Chapter 3: Specific Aims 
Current delivery techniques for cellular therapies lack efficiency and localized delivery. Our 
technique utilizing fibrin microthread biological sutures have shown the ability to overcome these issues 
and have shown a higher cell engraftment rate as compared to the gold standard of intramuscular 
injection.15 However, the cell seeding efficiency onto the sutures is low and during implantation cells are 
subjected to shear forces as the sutures are pulled through the tissue. As a result, cells go unused after 
seeding and an uneven distribution of cells from the entry point to exit of the suture.15 Therefore to try 
and overcome these drawbacks, we propose the following specific aims:  
Specific Aim 1 – Increase cell quantity and seeding efficiency on fibrin microthread biological sutures. 
We will evaluate two methods to increase the cell quantity. The first is that more cells will 
attach to surface-treated fibrin microthread sutures. We will study a charge enhancer, poly-l-lysine, and 
an extracellular matrix protein, vitronectin, on the surface of the fibrin microthread sutures. The second 
method will be increasing the seeding time of the cells on the uncoated control microthread biological 
sutures. Sutures will be seeded with hMSCs for 24 hours then allowed to incubate for an additional 24 
hours. hMSCs are chosen for seeding experiments because of their clinical relevance and for comparison 
to prior work done in our lab. To evaluate the effectiveness of the coatings and increased seeding time 
we will test cell attachment with a DNA assay to determine the cell number on the biological sutures. 
We will also evaluate how each method affected cellular alignment through image analysis.  
Specific Aim 2 – Develop an in vitro method to mimic the shear loading on hMSCs comparable to those 
applied during implantation. 
We hypothesize that hMSCs which experience a shear force load will detach from the biological 
sutures resulting in a lower cell number as compared to non-loaded sutures. To test this aim, we will 
create an in vitro shear loading model with the use of a centrifuge. An in vitro centrifugal shear model 
will be used as compared to an in vivo implantation because it is faster, reproducible, and inexpensive 
and does not require the use of animals. Seeded biological sutures will be spun to produce additional 
shear stress on the cells. We will then evaluate how the spinning affects cell attachment with a DNA 
assay to determine cell number onto the control, coated, and increased incubation time biological 
sutures.      
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Chapter 4: Aim #1: Increase Cell Quantity and Seeding Efficiency on 
Fibrin Microthread Biological Sutures 
4.1: Introduction 
Fibrin microthread biological sutures have shown the ability to effectively and locally deliver 
cells to the myocardium as compared to other methods, but the low efficiency of hMSC seeding on the 
sutures results in wasted cells. We explored the use of cellular attachment and adhesion promoter 
coated biological sutures and increased incubation time as ways to overcome this shortfall. We then 
evaluated the cellular attachment onto the sutures and how each modification affects the cellular 
alignment.   
4.2: Methods  
4.2.1: Fibrin Microthread and Bundle Production 
 As previously described,12 fibrin microthreads are created with a 1ml syringe of thrombin (150µL 
of an 8 U/200µL 20mM HEPES buffered Saline thrombin solution, diluted in 850µL of 40mM calcium 
chloride; Sigma Aldrich, St. Louis, MO) and a 1ml syringe of fibrinogen (70 mg/mL; Sigma Aldrich) both 
derived from bovine plasma are inserted into a blending applicator tip. The two conjoined syringes are 
then placed in a syringe pump set to a flow rate of 0.23ml/min, the combined solution is extruded 
through a 0.38 mm polyethylene tubing (Becton Dickinson) into a 10 mM HEPES bath (pH 7.4, room 
temperature; Figure 4). The fibrin microthreads are allowed to form in the bath for 15 minutes. They are 
then removed from the bath, stretched, allowed to air dry, and then stored in a room temperature 
desiccator. 
 
Figure 4: Fibrin microthread scanning electron micrograph (left) and extrusion diagram (right)
12
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 Based on prior work bundles were created as follows,15 12 fibrin 
together on top of a dark background (all > 16cm). To capture all the 
The taped end was then clamped in an elevated position allowing the 
deionized water (dH2O) were placed on the taped end of the threads, 
droplets followed the length of the threads. After hydration the free end 
create a single entwined 12 fibrin microthread bundle of approximately 
can be found in Appendices 
Appendix A: Fibrin Microthread Creation 
4.2.2: Suture Formation, Sterilization and Cell Seeding 
 As previously described,15 microthread bundles (≈16 cm long, 12 entwined fibrin microthreads) 
were cut into 4 cm lengths. The lengths were threaded through the eye of surgical suture needle (size 
#18, 3/8” circle, tapered; Securos Surgical, Fiskdale, MA; Figure 5 A, F). The bundle was then hydrated in 
dH2O and the needle was positioned in the middle of the 4cm length bundle. The two free ends of the 
bundle were folded back to create a 2cm suture construct (B, C, G). The two ends were then gently 
twisted (D) to create a secure entwined suture construct in which the body contains 24 threads and 12 
threads lopping through the eye of the needle (E, H).  
 
Figure 5: Step by step process of biological suture creation. A suture needle is placed in the middle of a 4cm microthread 
bundle (A, F). The bundle was hydrated and the two free ends are brought together (B, C, G). The two ends are twisted 
together (D) to create a single entwined biological microthread suture (E, H). 
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Prior to cell seeding, microthread sutures were placed into gas-permeable SilasticTM tubing (1.98 
mm ID, Dow Corning, Midland, MI; Figure 6 B). A slide clamp (Qosina, Edgewood, NY) was then fixed at 
the needle end of the tube construct, creating a seal (C). A 27-gauge needle was inserted (Becton 
Dickinson and Co., Franklin Lakes, NJ) into the tubing next to the surgical needle to facilitate cell seeding 
(D). An additional slide clamp was placed on the tube construct. The clamp did not seal the construct to 
facilitate gas sterilization inside the tube. The constructs were then ethylene-oxide gas sterilized for 12 
hours. 
 
Figure 6: Step by step assembly of the bioreactor. The bioreactor consists of a 27 gauge hypodermic needle, two slide clamps, 
1.98mm ID silicone tubing, and the biological suture (A). The first step was inserting the suture into the tubing (B), and then 
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one of the slide clamps was secured over the tube and the suture needle (C). The hypodermic needle was then inserted into 
the suture needle end of the bioreactor to act as a cell injection port, at this point the suture was ethylene oxide gas 
sterilized (D). After the cell suspension was injected into the bioreactor the second slide clamp was secured to seal the open 
end of the tubing (E). 
 For cell seeding, a 100µl solution of 1 x 106 cell/mL or 50,000 cells per cm of suture was used to 
seed the microthread suture. Sutures were hydrated in 1x DPBS (Mediatech, Inc., Manassas, VA) for 20 
minutes prior to the addition of cells. The cell solution was withdrawn into a sterile 1ml syringe and the 
syringe was then attached to the 27 gauge hypodermic needle. 100µl (≈100,000 cells) was injected into 
the tubing construct and onto the suture. The seeded suture constructs were then placed into vented 50 
mL conical tubes (2 constructs per conical tube), and the conical tubes were placed in a MACSmix™ 
rotator (Miltenyi Biotec, Bergisch Gladbach, Germany; Figure 7) set at 4 rpm. The rotator was then 
placed into a 37°C incubator (5% CO2, atmospheric gas concentrations), and the sutures were incubated 
for 24. A detailed protocol can be found in Appendix B: Seeding Fibrin Microthread Biological Suture. 
 
Figure 7: Loaded MACSmix™ rotator 
4.2.3: Cell Culture 
 Culture of hMSCs (Lonza Inc., Walkersville, MD) was done according to aseptic techniques. 
hMSCs were thawed from a 10% Dimethyl Sulfoxide (DMSO; Sigma Aldrich), Dulbecco’s Modified Eagles 
medium (DMEM; with L-glutamine and 4.5 g/L glucose; Lonza, Inc.) culture medium. hMSCs were 
seeded at a concentration of ≈7000 hMSCs per cm2 on standard tissue culture plastic. Culture medium 
was DMEM, 10% fetal bovine serum (FBS; PAA Laboratories, Inc., Dartmouth, MA), and 1% 
penicillin/streptomycin (Gibco, Grand Island, NY). Cells were released from the tissue culture plastic with 
0.25% trypsin ethylenediaminetetraacetic acid (trypsin EDTA; Cellgro® Mediatech, Inc., Manassas, VA). 
Cells used for experiments were between passages 6 – 9. A detailed protocol for cell culture and 
passaging cells can be found in Appendix C: Human Mesenchymal Stem Cell Culture     
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4.2.4: Surface Modification of Biological Microthreads 
Prior to cell seeding, microthread sutures were removed from their tube constructs and coated 
with either a 0.1mg/mL poly-l-lysine (Electron Microscopy Sciences, Hatfield, PA) or 0.5µg/mL 
vitronectin (Sigma Aldrich) derived from human plasma in 0.1mL and 0.5mL of sterile dH2O for poly-l-
lysine and vitronectin respectively for an individual suture, according to manufactures 
recommendations. This corresponds to 40µg/cm2 and 1.0µg/cm2 of poly-l-lysine and vitronectin 
respectively, based on suture surface area the calculation. Sutures were allowed to incubate in the 
solutions for 2.5 hours at 37°C after incubation the solution was discarded. The suture were then air 
dried in a sterile environment and placed back into the tubing constructs and rinsed with 0.25ml 1x 
DPBS prior to cell seeding. 
4.2.5: Qualitative Verification of Coatings 
 To verify if poly-l-lysine and vitronectin were successfully coating fibrin microthread sutures 
were qualitatively assessed for fluorescent signal. Poly-l-lysine coating was verified by incubating and 
coating sutures in a 0.1mg/ml Fluorescein isothiocyanate (FITC) conjugate poly-l-lysine (Sigma Aldrich) in 
0.1mL of dH2O per suture (40µg/cm
2) for 2.5 hours at 37°C. After incubation the solution was discarded. 
Sutures were then rinsed with PBS x2 and cover slip spacers (Grace Bio-Labs, Bend, OR) were added. 
Samples were sealed with Cytoseal™ 60 (Richard Allan Scientific, Kalamazoo, MI) and coverslips were 
added.  
For vitronectin sutures were incubated in 0.5µg/mL vitronectin for 2.5 hours at 37°C. After 
incubation sutures were rinsed with PBS x3 and stained using immunohistochemistry. The primary 
antibody was a 1:100 dilution of mouse monoclonal anti-vitronectin (Sigma Aldrich) in 1% bovine serum 
albumin (BSA; Sigma Aldrich) and was incubated overnight at 4°C. The sutures were rinsed with PBS x3 
and then treated with the secondary antibody 2.5:100 rabbit anti-mouse AlexaFlour 488 (Invitrogen, 
Carlsbad, CA) in 1% BSA for one hour. Sutures were then rinsed with PBS x3 and cover slip spacers, 
mounting media and coverslips were added.  
Sutures were visualized with a Leica DM LB2 fluorescent microscope (Leica Microsystems Inc., 
Buffalo Grove, IL) and images were captured with a Leica DFC 480 camera. Images were then 
qualitatively assessed for fluorescent signal coverage on the suture. A detailed protocol can be found in 
Appendix D: Vitronectin Immunohistochemistry Staining 
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4.2.6: Extended Culture on Seeded Biological Sutures 
 After the initial 24 hour seeding process, the seeded biological microthread sutures were left in 
the bioreactors and allowed to incubate for an additional 24 hours. The sutures remained in the original 
cell suspension, 50 mL vented conical tubes, tube rotator and 37°C incubator (5% CO2, atmospheric gas 
concentrations). 
4.2.7 Qualitative Assessment of Cells on Seeded Biological Microthreads 
Cells were qualitatively assessed with the use of fluorescent staining. Sutures were removed 
from the tube construct and rinsed with DPBS. Sutures were then fixed in 4% paraformaldehyde in PBS 
(Boston BioProducts, Ashland, MA) for 10 minutes. Sutures were then rinsed in PBS x2, cells were then 
permeabilized using 0.25% Triton X-100(Sigma Aldrich) for 10 minutes. Rinsed in PBS x2 and then 
blocked with 1% BSA for 30 minutes. Cytoskeletal filament actin (f-actin) present in microtubules and 
microfilaments were stained with 2.5:100 phalloidin (conjugated to AlexaFlour 488; Invitrogen, Carlsbad, 
CA) in PBS for 30 minutes. Sutures were then rinsed with PBS x2. Cell nuclei were counter-stained with 
1:6000 Hoechst dye (Invitrogen) in PBS. Sutures were rinsed with PBS x2. Cover slip spacers were added. 
Samples were sealed with Cytoseal™ 60 and coverslips were added. Sutures and cells were visualized 
with a Leica DM LB2 fluorescent microscope and images were captured with a Leica DFC 480 camera. 
Images were then qualitatively assessed for cell morphology and cell coverage on the suture. A detailed 
protocol can be found in Appendix E: Fluorescent Staining of Seeded Sutures. 
4.2.8: Calculation of Theoretical Max Seeding Number  
 The theoretical max cell attachment to the fibrin microthread sutures was based on prior 
work91, first the surface area available for cell attachment on a 24 microthread suture was calculated. To 
estimate the surface area we approximated the circumference of the suture and multiply by its length.  
 A theoretical pattern for the 24 microthreads was created which can be seen in Figure 8A 
because the suture is not a perfect cylinder we must create a theoretical shape for the suture based on 
the arrangement of 24 microthreads. From this pattern we can calculated the circumference to the 
suture. Only 14 of the threads are on the outer surface of the suture, while the other 10 threads are 
buried in the center of the suture and are not included in the circumference calculation. Of those 14 
threads only the outward facing portions of the thread will be counted in the circumference.  Based on 
Figure 8B there are two different levels of exposure, 8 threads have 50% of the surface area exposed 
and 6 have 66% exposed. Based off of this information, the circumference of the suture was calculated 
as follows: 
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Suture Circumference = α(πd)β  
 
Where d was the approximate diameter of a single hydrated microthread based off of prior 
work  (100µm).12 α was the approximate percentage of the microthread available for cell attachment in 
the bundle or the outward facing portion. There are two levels of exposure 50% and 66% so there will be 
two α values (α1 = 50%, α2 = 66%). β was the number of microthreads have that correspond to each 
particular percentage of exposure where β1  corresponds to 50% or α1  and β2  corresponds to 66% or α2 
(β1 = 8, β2 = 6; Figure 8). The approximate surface area was determined by multiplying the circumference 
by the length. The total cell attachment was then calculated by dividing the surface area by the average 
hMSC area (1,255 ± 911µm2).91 The final equation for suture surface area was calculated as follows: 
Suture Circumference = α1(πd)β1 + α2(πd)β2 
Surface Area = (α1(πd)β1 + α2(πd)β2)(suture length) 
  Cells on suture = ((α1(πd)β1 + α2(πd)β2)(suture length)) / cell surface area 
 
 
Figure 8: Determining the circumference of a microthread suture. A theoretical shape of a 24 microthread sutures was 
created (A), only the microthreads on the outside of the suture will be counted in the circumference (B), and only the outer 
surface of those microthreads will be counted in the circumference (C). 
4.2.9: Quantification of Cell Number and Seeding Efficiency Using CyQUANT DNA Assay 
 Cells attached to the microthread sutures were quantified with the use of CyQUANT® Cell 
Proliferation Assay Kit (Invitrogen) according to manufacturer’s protocol. Seeded microthread sutures 
were removed from the surgical suture needle, rinsed with DPBS, and placed in 100µl of ultra-pure dH2O 
(Millipore, Billerica, MA). The sutures are then placed in a -80°C freezer. 50µl of CyQUANT GR dye was 
added to a 20ml of 1x cell lysis buffer. After the sutures were in the freezer for at least one hour the 
A C B 
six 
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sutures were removed and allowed to thaw. 400µl of the dye and lysis buffer were added to the sutures 
and vortexed (Figure 9). 100µl of the solution was then aliquoted to wells of a 96 well plate and placed 
in a plate reader with a 480nm excitation, 520nm absorption (Figure 10). Cell number was calculated 
with the use of a standard curve (Figure 11). To verify cell lysis and to make sure all cells were counted, 
threads were stained with Hoechst (Invitrogen) post freezing and addition of the cell lysis buffer. 
Seeding efficiency was calculated by dividing the cell number by 50,000 cells per cm suture.  A detailed 
protocol can be found in Appendix F: CyQUANT DNA Assay Protocol. 
 
Figure 9: Suture preparation for CyQUANT analysis. Seeded sutures are removed from the needle (A), placed into deionized 
water (B), the suture is then placed in a -80°C freezer (C), the suture is thawed, and CyQUANT GR dye and cell lysis buffer is 
added (D). 
 32 
 
 
Figure 10: Example of a 96 well plate for CyQUANT assay. The first four columns are used for a serial dilution of known cell 
numbers and the creation of a standard curve.  The other columns are used for each experiment and rows for individual 
samples.  
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Figure 11: The creation of a standard curve based on known cell densities allows for the calculation of cell attachment to the 
sutures. 
 
4.2.10: Quantification of Alignment and Elongation  
 As previously described,
92
 sutures were seeded with approximately 100µL of 1 x 10
6
 hMSCs/mL after 24 hours of 
after 24 hours of seeding sutures were stained with Hoechst nuclear dye. Stained sutures were imaged at 20x magnification (
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at 20x magnification (
 
Figure 12 A). Images were taken where nuclei were present including both areas of high and low cell density. Nuclei were 
analyzed using the image analysis software ImageJ (NIH, Bethesda, MD).  Due to the 3 dimensional shape of a suture, out of 
focus areas of each image were cropped and only in focus areas were analyzed. Intensity thresholds were applied to the 
images and using the particle detection program an ellipse was fit to the nuclei (
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Figure 12 B). Angle measurements were taken along the major axis of the ellipse and the long axis of the threads in relation 
to the horizontal (x-axis) or 0° (
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Figure 12; A & C). The nuclear angle was then normalized to the thread angle to determine nuclear 
alignment in relation to the individual microthread. Nuclear elongation was also determined with a ratio 
of the major axis to the minor axis (
 
Figure 12 C). Calculation for nuclear angle and elongation can be seen in 
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Figure 12 D. Any cell with an elongation ratio of less than 1.2 was considered circular and not included in 
the nuclear alignment data. Data from each image was then compiled into a single spread sheet for each 
suture modification. Data was then analyzed for average nuclear angle and percent aligned nuclei. 
Nuclei were considered aligned to the thread if the cellular angle was within less than 10° of the thread 
angle.89,93 A detailed protocol can be found in Appendix G: Nuclear Alignment and Elongation 
Quantification. 
 
Figure 12: Calculation of nuclear alignment and elongation with the use of image analysis software. Nuclei were visualized 
with Hoechst nuclear dye and imaged at 20 times magnification and the angle of the microthread is measured in relation to 
the X-axis (A), an ellipse was fit to each nucleus (B), the angle of the elliptical major axis is determined in relation to the X-
axis and the lengths of the major and minor axis are determined (c), nuclear alignment was determined after normalizing the 
nuclear angle to the thread angle and nuclear elongation was calculated by dividing the major axis by the minor axis (D).  
4.2.11: Statistical Analysis 
 Statistical differences were determined with SigmaPlot (OriginLab, Northampton, MA). For 
multiple groups one-way ANOVA with a Tukey post-hoc and for two groups Student’s T-tests were 
performed. Data was considered significant with a p value < 0.05. All data was reported in the following 
format mean ± SEM (standard error of mean), unless stated otherwise stated. 
4.3: Results 
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4.3.1: Verification of Coatings on Biological Sutures 
 To verify the coatings on the sutures fluorescent images were taken of FITC conjugated poly-l-
lysine and immunohistochemistry stained vitronectin coatings. Fluorescence was present in both poly-l-
lysine and vitronectin coated threads (Figure 13 and Figure 14, respectively). There was more 
fluorescence present in both types of coated sutures when compared to control threads.  
 
Figure 13: Verification of poly-l-lysine coating on sutures; FITC conjugated Poly-l-lysine coated suture (left) control suture 
(right) 
 
Figure 14: Verification of vitronectin coating on sutures; Vitronectin coated sutures(A-C), control suture (D-F), 
primary/secondary positive( A,D), primary negative and secondary positive (B,E), primary/secondary negative (C,F) 
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4.3.2: Qualitative Assessment of Cells on Coated Biological Sutures 
   
Control Biological Microthread Sutures 
 hMSCs attached to the control biological sutures. The cells spread out along the long axis of the 
suture and retained their typical spindle or trapezoidal morphology (Figure 16). Filament-actin was 
visible in all the cells and run in the directions of the adhesion sites (white arrows).  Cells appeared to 
preferentially settle in the crevice between neighboring microthreads (outlined microthreads with white 
dashed line). When this space was occupied they begin to spread out over the cylindrical short axis of 
the microthread. There was area where no cells attached (white dashed circle, Figure 15) however 
groups of cells were present along the length of the sutures and  around the suture circumference (solid 
white circles). 
 
Figure 15: Visualization of cells on control suture at 10 times magnification; blue - Hoechst (nuclei), green - Phalloidin (f-
actin), white circle – areas of high cell density, white dashed circle – area of no cells or low density, white bar- 1000µm 
Control 
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Figure 16: Visualization of cells on control suture at 20 times magnification; blue - Hoechst (nuclei), green - Phalloidin (f-
actin), dashed white lines – microthread borders, white arrows – spread out cells 
Poly-L-Lysine Coated Sutures 
 hMSCs that adhered to the poly-l-lysine coated suture did not spread out. Many of the cells 
appeared spherical with thin cellular projections. F-actin was not clearly visible in the spherical cells and 
the green signal was diffuse throughout the cytoplasm (white arrows, Figure 18). Cells were not evenly 
distributed throughout the sutures. There was area where no cells attached (white dashed circle, Figure 
17) however it did not appear that cells preferred certain areas as groups of cells were present along the 
length of the sutures and  around the suture’ circumference (solid white circles). 
 
Figure 17: Visualization of cells on poly-l-lysine coated suture at 10 times magnification; blue - Hoechst (nuclei), green - 
Phalloidin (f-actin), white circle – areas of high cell density, white dashed circle – area of no cells or low density, white bar- 
1000µm 
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Figure 18: Visualization of cells on poly-l-lysine coated suture at 20 times magnification; blue - Hoechst (nuclei), green - 
Phalloidin (f-actin), dashed white lines – microthread borders, white arrows – cells with circular phenotype  
Vitronectin Coated Sutures 
 The adherent hMSCs on the vitronectin coated sutures were found randomly distributed along 
the length of the sutures; 360° around the sutures (white circles, Figure 19) and some areas had no cell 
attachment (white dashed circles). Cells appeared to align along the long axis. It appeared that the high 
density of cells in some areas had restricted them from fully spreading out and aligning (red circle, 
Figure 20). Cells that had sufficient space did spread aligned along the long axis of the suture (red 
dashed circle). The green f-actin signal was clearly visible with the formation of cytoskeletal tubules in all 
cells (white arrowheads). Similar to the unmodified sutures cells appeared to prefer to adhere to the 
gap or junction between two microthreads (outlined microthreads with white dashed line). If this area 
was occupied, hMSCs spread out over the cylindrical short axis.  
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Figure 19: Visualization of cells on vitronectin coated suture at 10 times magnification; blue - Hoechst (nuclei), green - 
Phalloidin (f-actin), white circle – areas of high cell density, white dashed circle – area of no cells or low density, white bar- 
1000µm 
 
Figure 20: Visualization of cells on vitronectin coated suture at 20 times magnification; blue - Hoechst (nuclei), green - 
Phalloidin (f-actin), dashed white lines – microthread borders, white arrows – aligned cytoskeleton, red circle – cells at high 
density that could not spread out, red dashed circle – spread out cells  
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4.3.3: Calculation of Theoretical Maximum Seeding Density 
 The theoretical max cell attachment to a fibrin microthread suture was calculated based on 
prior work and Figure 8.91 The grooves created by bundling the microthreads into sutures increased the 
surface area as compared to a cylinder and therefore increased the overall area for cell attachment. 
Based on an assumed cell area the theoretical max seeding of hMSCs was calculated to be 19,920 cell 
per cm of suture. 
 
Suture Surface Area = .5(.1π)8 + .66(.1π)6 = 2.50mm * 10mm = 25.0mm2 
Theoretical max cell attachment = 25.0mm2 / .001255mm2 = 19,920 cells per cm 
4.3.4: Quantifying Cell Number and Seeding Efficiency on Coated Biological Sutures  
 Cell number and attachment to sutures was quantified with the use of CyQUANT® cell 
proliferation assay. In control sutures (n=20; Table 1), 6,821 ± 707 hMSCs per cm attached to the fibrin 
based biological suture. Poly-l-lysine coating (n=8) resulted in 4,227 ± 1,003 hMSCs per cm.  The 
maximum number of cells attached to fibrin based biological sutures resulted from vitronectin coating 
(n=8) with 19,604 ± 1,829 hMSCs per cm which was the same as theoretical max cell number onto the 
sutures. The vitronectin coated threads was significantly higher than both the control and poly-L-Lysine 
coated sutures (p<0.05; Figure 21). Compared to control fibrin microthread sutures, poly-l-lysine coating 
resulted in a decrease of 38% whereas vitronectin coating increased cell quantity by 187%.  With every 
suture modification the aim was to get a sample size of 8, which each modification a control suture was 
seeded and cell number was quantified to verify accurate seeding. The sample size for control sutures 
was larger than all the modifications for that reason.   
 Table 1: Effect of coatings on cell number 
Suture Type 
Average Cell Number ± SEM 
(hMSCs/cm) 
Control  
n=20 
6,821 ± 739 
Poly-l-lysine  
n=8 
4,226 ± 1,003 
Vitronectin  
n=8 
19,604 ± 1,829 
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Figure 21: Effect of coating sutures to mean cell attachment (± SEM). Sample sizes for culture (blue), poly-l-lysine (red), and 
vitronectin (green) are 20, 8, and 8, respectively. Brackets indicate statistical difference, one-way ANOVA with Tukey post-
hoc p<0.05. 
 
 The seeding efficiency of coated biological sutures was calculated by dividing the cell number 
evaluated by CyQUANT® DNA assay by the cell seeding density of 50,000 hMSCs per cm of suture. 
Seeding efficiency for control sutures was 14 ± 1%. The seeding efficiency for poly-l-lysine and 
vitronectin coated sutures was 8 ± 2% and 39 ± 4%, respectively (Table 2 and Figure 22). The vitronectin 
coated threads was significantly higher than both the control and poly-L-Lysine coated sutures (p<0.05). 
Table 2: Effect of coatings on cell seeding efficiency 
Suture Type 
Cell Seeding Efficiency  
(Cell Attachment/Seeding Density) 
Control Sutures 
n = 20 
14 ± 1% 
Poly-l-lysine 
n = 8 
8 ± 2% 
Vitronectin 
n = 8 
39 ± 4% 
 
p < 0.05 
 45 
 
 
Figure 22: Effect of coatings on sutures to cell seeding efficiency. Seeding efficiency was determined by dividing the mean cell 
attachment (±SEM) by the seeding density. Sample sizes for culture (blue), poly-l-lysine (red), and vitronectin (green) are 20, 
8, and 8, respectively. Brackets indicate statistical difference, one-way ANOVA with Tukey post-hoc p<0.05. 
4.3.5: Qualitative Assessment of Increased Culture Time on Biological Sutures 
 Cells that adhered to the biological sutures then were incubated for an additional 24 hours were 
present throughout the length and width of the suture, but not at the same densities as the regular 
sutures there were also areas were no cells attached. Similar to the regular and vitronectin sutures the 
cells preferred to adhere in the gap or junction between two microthreads (microthreads outlined with 
white dashed lines, Figure 23). It appeared that the cells on these sutures were more spread out and 
aligned than cells on all other types of sutures. The green f-actin signal was present and it appeared that 
cell cytoskeletal tubules were aligning along the long axis of the sutures and lead to the adhesion sites 
(white arrows). 
Some sutures showed signs of degradation. Of the 30 total sutures used in the evaluation of this 
method for both specific aim 1 and 2, six sutures broke off the needle when trying to remove them from 
the bioreactor. Eight sutures completely degraded or had only fibrin microthread fragments floating in 
the bioreactor after incubation. Medium in the bioreactors was macro and microscopically visually 
inspected for signs of contamination and was found negative. The control suture that was incubated for 
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48 hours in cell media showed no signs of degradation for all experiments with increased incubation 
time.  
 
Figure 23: Visualization of cells on sutures after 48 hours of culture. blue - Hoechst (nuclei), green - Phalloidin (f-actin), 
dashed white lines – microthread borders, white arrows – aligned cytoskeleton 
4.3.6: Effect of Extending Culture Time on Cell Number and Seeding Efficiency   
 Following incubation, the cell number and attachment was quantified with CyQUANT® cell 
proliferation assay. Sutures that were given 24 hours of additional incubation time (n=6) had 
4,417±2,266 hMSCs per cm attached. This resulted in a 35% decrease in cell number when compared to 
control sutures (Table 3 and Error! Reference source not found.). The increase to 48 hours of culture 
time resulted in a 9±2% seeding efficiency (Table 4 and Figure 25). 
 
Table 3: Effect of culture time on cell number  
Suture Type 
Average Cell Number ± SEM 
(hMSCs/cm) 
Control – 24 hour 
n=20 
6,821 ± 739 
Control – 48 hour 
n=6 
4,417 ± 1,133 
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Figure 24: Effect of increasing culture time on control sutures to mean cell attachment (± SEM). Sample sizes for 24 hour 
(blue) and 48 hour seeding (purple) are 20 and 6, respectively. 
Table 4: Effect of culture time on seeding efficiency 
Suture Type 
Cell Seeding Efficiency  
(Cell Attachment/seeding density) 
Control - 24 Hour 
n = 20 
14 ± 1% 
Control - 48 Hour 
n = 6 
9 ± 2% 
 
 48 
 
 
Figure 25: Comparing the effect of increasing culture time on control suture to cell seeding efficiency. Seeding efficiency was 
determined by dividing the mean cell attachment (±SEM) by the seeding density. Sample sizes for 24 hour (blue) and 48 hour 
seeding (purple) are 20 and 6, respectively.  
  
4.3.7: Quantifying Alignment and Elongation on Sutures 
 It was determined that control sutures had a nuclear angle of 15.3±15.9° (n = 314, p<0.05, mean 
± standard deviation; Table 5 and Figure 26). Poly-l-lysine coated sutures had a nuclear angle of 
23.1±19.8° (n = 142), vitronectin had an angle of 27.5±23.7° (n = 687), and 48 hour cultured sutures had 
an angle of 30.3±15.9° (n = 307). The tissue culture plastic control had a nuclear angle of 49.03±24.4° (n 
= 209, p<0.05; Figure 27). Unmodified sutures had 49.9% of cells to be considered aligned (between 0-
10° of the angle of the sutures; Figure 29), poly-l-lysine had 29.6%, vitronectin had 28.8%, 48 hour 
culture had 23.5% and tissue culture plastic had 6.7%. Results for overall cellular alignment can be found 
in Table 6 and Figure 28. It was determined that only 2.5% of cell nuclei were considered circular on 
unmodified sutures (a nuclei considered circular had an elongation ratio of < 1.2), poly-l-lysine had 
16.5% (Figure 31), vitronectin had 10.9% , 48 hour culture had 4.1% and tissue culture plastic had 9.9% 
of cells. Results for circular nuclei can be found in Table 7 and Figure 30.  
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Table 5: Average nuclear angle 
Seeding Material Average Nuclear Angle ± SD 
Tissue Plastic 
n = 209 
49.03 ± 24.4° 
Control Suture 
n =314 
15.28 ± 15.9° 
Poly-l-lysine Suture 
n = 142 
23.1 ± 19.9° 
Vitronectin Suture 
n = 687 
27.51 ± 23.7° 
48 Hour Culture 
n = 307 
30.26 ± 23.9° 
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Figure 26: Effect of modifications on mean nuclear angle (±SD). Sample size for each modification were as follows, TCP = 209, 
control = 314, poly-l-lysine = 142, vitronectin = 687 and 48 hour culture = 307. Brackets indicate statistical difference, one-
way ANOVA with Tukey post-hoc p<0.05. 
 
Control 
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Figure 27: Nuclear shape and direction are indicators of overall cellular shape and direction on tissue culture plastic (TCP). 
Cells were visualized with Hoechst nuclear dye (nuclei – blue) and phalloidin (f-actin – green; upper right) at 20 times 
magnification. Nuclear outline was highlighted with white while nuclear direction was highlighted with white arrows (upper 
right). Cellular outline was highlighted with white while cellular direction was highlighted with white arrows (lower left). The 
overlay of the highlighted nuclear and cellular shape and direction (lower right) shows that elliptical nuclei are found in 
elongated cells and nuclear direction matched overall cellular direction. Cellular direction was randomly oriented on the 
topographically flat TCP. 
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Table 6: Percent aligned nuclei 
Seeding Material Percent Aligned Nuclei 
Tissue Plastic 
n = 209 
7% 
Control Suture 
n = 314 
50% 
Poly-l-lysine Suture 
n = 142 
30% 
Vitronectin Suture 
n = 687 
29% 
48 Hour Culture 
n = 307 
23% 
   
 
Figure 28: Comparing the percentage of nuclear aligned to the thread amongst the modifications made to the sutures and 
tissue culture plastic (TCP, cell aligned to the x- axis). A nuclei was considered aligned if nuclear angle was within 10° of the 
thread angle. Sample size for each modification were as follows, TCP = 209, control = 314, poly-l-lysine = 142, vitronectin = 
687 and 48 hour culture = 307. 
 53 
 
 
Figure 29: Nuclear shape and direction are indicators of overall cellular shape and direction on control sutures. Cells were 
visualized with Hoechst nuclear dye (nuclei – blue) and phalloidin (f-actin – green; upper right) at 20 times magnification. 
Nuclear outline was highlighted with white while nuclear direction was highlighted with white arrows (upper right). Cellular 
outline was highlighted with white while cellular direction was highlighted with white arrows (lower left). The overlay of the 
highlighted nuclear and cellular shape and direction (lower right) shows that elliptical nuclei are found in elongated cells and 
nuclear direction matched overall cellular direction. Cells aligned along the direction of the long axis of individual 
microthreads (white dashed arrows). 
 
 54 
 
Table 7: Percent circular nuclei 
Seeding Material Percent Circular Nuclei 
Tissue Plastic 
n = 209 
10% 
Control Suture 
n = 314 
2% 
Poly-l-lysine Suture 
n = 142 
16% 
Vitronectin Suture 
n = 687 
11% 
48 Hour Culture 
n = 307 
4% 
 
 
Figure 30: Comparing the percentage of circular nuclei amongst the modifications made to the sutures and tissue culture 
plastic (TCP). A nuclei was considered circular if the elongation ratio was less than 1.2. Sample size for each modification 
were as follows, TCP = 209, control = 314, poly-l-lysine = 142, vitronectin = 687 and 48 hour culture = 307. 
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Figure 31: Nuclear shape is an indicator of overall cellular shape on poly-l-lysine coated sutures. Cells were visualized with 
Hoechst nuclear dye (nuclei – blue) and phalloidin (f-actin – green; upper right) at 20 times magnification. Nuclear shape 
(upper right) and overall cellular shape (lower left) was highlighted with white circles. The overlay of the highlighted nuclear 
and cellular (lower right) shows that circular nuclei are found in circular cells while elliptical nuclei are found in elliptical 
shaped cells. 
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Chapter 5: Aim #2: Develop an In Vitro Method to Mimic the Shear 
Loading on hMSC Comparable to Those Applied During Implantation. 
5.1: Introduction 
During implantation of fibrin microthread biological sutures into heart tissue it was noticed that 
cells tended to engraft closer to the entry site of the suture as compared to the exit point.  It has been 
suggested that this could be due to shear forces on the cells as the suture was pulled through the tissue 
which leads to a loss of cells and a non-uniform cell distribution.   We developed a system to model and 
study the effects of shear loading on cell-seeded microthread biological sutures in vitro  using a 
centrifuge. We used this system to study the potential increases in cellular adhesion force as a function 
of altered suture coatings, including vitronectin and poly-l-lysine, and cell incubation times.    
5.2: Methods 
5.2.1: Shear Model 
 Fibrin microthread bundles and seeded biological sutures were created and seeded according to 
the protocols in sections 4.2.1: Fibrin Microthread and Bundle Production and 4.2.2: Suture Formation, 
Sterilization and Cell Seeding, respectively. Biological microthread sutures were coated according to the 
protocol seen in section 4.2.4: Surface Modification of Biological Microthreads. After 24 or 48 hours 
seeding the microthread sutures were removed from the tube construct and rinsed in DPBS. They were 
then placed in modified 15 ml conical tubes full of 37°C DPBS. The microthread sutures were clamped 
and positioned so that the suture freely floats in the DPBS and did not contact any surfaces. The conical 
tubes were then placed in a swinging bucket centrifuge. The sutures were then spun at either 280 rpm 
(≈10 x force of gravity; g10) or 620 rpm (≈50 x force of gravity; g50) for 5 minutes (Figure 32). g-Force 
measurement was calculated at the eye of the needle and the corresponding gradient can be seen in 
Figure 34. Sutures were then removed from the surgical suture needle and processed for quantitative 
and qualitative analysis according to sections 4.2.7 Qualitative Assessment of Cells on Seeded Biological 
Microthreadsand 4.2.9: Quantification of Cell Number and Seeding Efficiency Using CyQUANT DNA 
Assay. 
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Figure 32: g-Force calculations to determine the rpm for spinning sutures at g10 (left) and g50 (right). 
 
Figure 33: Bucket angle at g10 and g50. During spinning the buckets are not completely horizontal and to calculate the g-force 
on the sutures the bucket angle and the corresponding sutures angle needs to be determined. At g10 (top right) and g50 
(bottom right) the bucket angle is 84.28° and 88.84°, respectively.   
 
 
G g10 
g50 
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Figure 34: g-Force gradient on suture during spinning. g-Force increases along the length of the sutures from the eye of the 
needle to the end of the suture. The measurements for g10 are in the center column and g50 in the right column. 
 
5.2.2: Statistical Analysis 
 Statistical differences were determined with SigmaPlot (OriginLab, Northampton, MA) and one-
way ANOVA with Tukey post-hoc for multiple groups. All data was considered significant with a              
p-value < 0.05 and reported in the following format unless stated otherwise mean ± SEM (standard error 
of mean). 
5.3: Results 
5.3.1: Effect of Shear Model on Coated Biological Sutures   
Results for the shear loading test can be seen in Table 8. With the control sutures it was 
determined that 3,938±650 hMSCs per cm (57% remaining) were still attached after g10 (n=8) and 
1,823±617 hMSCs per cm (27% remaining) after 50g (n=7; p<0.05; Figure 35). Poly-L-Lysine coated 
sutures resulted in 2,033±522 (n=6, 30% compared to unspun control sutures) and 2,228±514 (n=6, 
 59 
 
33%) hMSCs for g10 and g50, respectively (Figure 36). Vitronectin coated sutures resulted in 13,789±3,280 
(n=6, 202%) and 5,394±2000 (n=6, 79%) hMSCs for g10 and g50 respectively (Figure 37). For the g10 
Vitronectin and poly-l-lysine coated sutures were statistically different (Figure 38). In the control group 
we attempted to get a sample size of 8 sutures for each g-force. When attempting g50 with the control 
group one suture broke from the needle during spinning so cell number was not quantified. In the 
coating groups we aimed for a sample size of 6 sutures and no sutures were lost during testing.  
Table 8: Effect of coating and increasing g-force on cell number 
Suture Type 
Cell Number ± SEM (hMSCs/cm) 
g1 g10 g50 
Control  
6,821 ± 739 
n = 20  
3,938 ± 650 
n = 8 
1,822 ± 616 
n = 7 
Poly-l-lysine  
4,226 ± 1,003 
n = 8 
2,032 ± 522 
n = 6 
2,228 ± 514 
n = 6 
Vitronectin  
19,604 ± 1,130 
n = 8 
13,799 ± 3,280 
n = 6 
5,393 ± 2,000 
n = 6 
 
 
Figure 35: Effect of increasing g-force on mean cell attachment (± SEM) to control sutures. Sample sizes for vitronectin coated 
are 20, 8, and 7 for g1, g10, and g50, respectively. Brackets indicate statistical difference, one-way ANOVA with Tukey post-hoc 
p<0.05 
p < 0.05 
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Figure 36: Effect of increasing g-force on mean cell attachment (± SEM) to poly-l-lysine coated sutures. Sample sizes for 
vitronectin coated are 8, 6, and 6 for g1, g10, and g50, respectively. Brackets indicate statistical difference, one-way ANOVA 
with Tukey post-hoc p<0.05 
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Figure 37: Effect of increasing g-force on mean cell attachment (± SEM) to vitronectin coated sutures. Sample sizes for 
vitronectin coated are 8, 6, and 6 for g1, g10, and g50, respectively. Brackets indicate statistical difference, one-way ANOVA 
with Tukey post-hoc p<0.05 
p < 0.05 
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Figure 38: Comparison of control (blue), poly-l-lysine (red), and vitronectin (green) sutures and the effect of  increasing g-
force on mean cell attachment (± SEM). Sample sizes for control sutures are 20, 8, and 7 for g1, g10, and g50, respectively. 
Sample sizes for poly-l-lysine coated sutures are 8, 6, and 6 for g1, g10, and g50, respectively. Sample sizes for vitronectin 
coated are 8, 6, and 6 for g1, g10, and g50, respectively. Brackets indicate statistical difference, one-way ANOVA with Tukey 
post-hoc p<0.05 
 
 
5.3.2: Effect of Shear Model on Increased Incubation Time Biological Sutures 
Increasing incubation time to 48 hours showed a consistent cell number with increasing g-force 
(Table 9). For sutures with an additional incubation time spinning resulted in 5,083±2,194, (n=10, 75%) 
and 4,775±1,908 (n=6, 70%) hMSCs for g10 and g50 respectively (Figure 39). The cell number on 48 hour 
sutures spun at g50 was significantly different when compared to the cell number on the control sutures 
and the standard 24 hours of seeding time as seen in Figure 40.  
 
p < 0.05 
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Table 9: Effect of culture time and increasing g-force on cell number 
 
 
 
 
 
 
 
 
Figure 39: Effect of increasing g-force on mean cell attachment (± SEM) to control sutures seeded for 48 hours. Sample sizes 
for are 6, 10, and 6 for g1, g10, and g50, respectively  
Suture Type 
Cell Number ± SEM (hMSCs/cm) 
g1 g10 g50 
Control (Standard 24 
hour seeding) 
6,821 ± 739 
 n= 20 
3,938 ± 650 
n = 8 
1,822 ± 616 
n = 7 
48 Hour Culture 
4,417 ± 1,133 
n = 6  
5,083 ± 1,097 
n = 10 
4,775 ± 954 
n = 6 
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Figure 40: Effect of increasing culture time and increasing g-force on mean cell attachment (± SEM) to control sutures (24 
hour standard seeding (blue) verses 48 hour seeding (purple)). Sample sizes for 24 hour seeding are 20, 8, and 7 for g1, g10, 
and g50, respectively. Sample sizes for 48 hour seeding are 6, 10, and 6 for g1, g10, and g50, respectively. Brackets indicate 
statistical difference, Student’s t-test p<0.05 
p < 0.05 
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Chapter 6: Discussion  
Current delivery methods for stem cell therapies and regenerative medicine lack efficiency and 
the ability to target specific regions of interest.32,50,55 Biological microthread sutures have shown the 
ability to overcome these difficulties. They can be seeded with hMSCs and then delivered to specific 
areas of the myocardium.13,15 The delivery of cell-seeded microthread sutures resulted in a higher 
engraftment rate as compared to the gold standard of intramuscular injection.15 Yet, there are some 
limitations with fibrin microthread sutures. The seeding efficiency is low (≈12%) so during seeding large 
numbers of cells go unused.15 The other issue occurs during implantation. It was observed that a higher 
number of hMSCs tended to engraft around the entry site of the suture as compared to the exit point. 
We hypothesized that this phenomenon resulted from shear loading onto cells during implantation as 
the suture was pulled through the tissue.15 Therefor we developed two aims; (1) increase cell number 
and seeding efficiency on the sutures, (2) develop an in vitro method to mimic the shear loading on 
hMSCs comparable to those experienced during implantation. We hypothesized that the addition of 
cellular attachment and adhesion promoters or increased incubation time for the cells on the 
microthread sutures would increase cell attachment, increase the seeding efficiency, and cellular 
adhesion. We evaluated both methods by qualitatively assessing the sutures and quantifying the cell 
number and cellular alignment. In order to test our second aim we developed an in vitro shear stress 
model with the use of a centrifuge and quantitatively assessed sutures for cell number post spinning.  
6.1: Specific Aim 1 
6.1.1: Sub-Aim 1 – Cellular Attachment and Adhesion Promoter Coated Sutures 
Biological Microthread Sutures 
 Our cell number for fibrin microthread sutures agreed with the work done by Guyette et al. 
(6,820±707 vs. 5,903±1,966 hMSCs per cm, respectively).15 There was some variation between the two 
numbers but the difference is not significant. Our work used a different quantification method than the 
work done by Guyette et al. and similar cell attachment numbers were found. The agreement between 
these two numbers further verifies the cell attachment to microthread sutures because similar numbers 
were found with different quantification methods.  
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Coated Biological Sutures 
In order to improve the ultimate efficiency of cell delivery, this work evaluated strategies to 
improve the seeding efficiency of biological microthread sutures. We employed well-known cell 
attachment promoters from two distinct classes as a means of accomplishing this. The first compound 
was a synthetic amino acid chain and charge enhancer, poly-l-lysine (Figure 41).84 The second coating 
used was the ECM protein vitronectin. Both are common coatings used to increase cell attachment and 
both were readily available, further driving their selection.73,75,77,84 They were also chosen because of 
their availability, low cost, and the familiarity in our lab. Concentrations of each promoter were chosen 
based on values found in literature. However, our final concentrations used were much higher than 
those values to assure a complete monolayer coating on each suture. We were able to achieve a 
complete coating which was qualitatively verified by coating sutures with fluorescent labeled poly-l-
lysine and immunohistochemical staining for vitronectin. Future work will have to evaluate the cell 
attachment response to different coating concentrations. This will optimize the coating concentrations 
for cellular attachment and prevent waste after coating saturation.    
 
Figure 41: Chemical structure of poly-l-lysine hydrobromide
85
 
The addition of poly-l-lysine resulted in a decrease in cell attachment, 4,227 ± 1,003 hMSCs per 
cm or a 38% decrease as compared to control sutures. This decrease in cell number could be due to a 
change in surface charge on the sutures, which ultimately changes interactions with serum proteins in 
the media, the cell membrane, and overall cell binding.85 This alteration could block or change a binding 
domain that is important for hMSC attachment to fibrin. Further suggesting this change was the 
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morphology on poly-l-lysine coated sutures. hMSCs exhibited a circular phenotype on the poly-l-lysine 
coating which is different from the trapezoidal or spindle shape of those on control sutures. The change 
in phenotype could be a sign that the hMSCs are beginning to differentiate. Poly-l-lysine has been used 
to coat surfaces to aid the differentiation of hMSCs.84,94,95 The phenotype of the hMSCs with the circular 
cell body and the axonal like projections after 24 hours on the sutures match the phenotype of hMSCs 
that have undergone neuronal differentiation after 48 hours as seen in Figure 42.95 Further tests and 
staining for differentiation markers would be needed to validate this theory. 
 
 
Figure 42: Comparing morphology of hMSCs attached to poly-l-lysine coated sutures(left) to hMSCs seeded onto poly-l-lysine 
coated polystyrene undergoing neuronal differentiation(right)
95
. Cellular projections similar to neuronal axons are 
highlighted with white arrows; blue – Hoechst (nuclei), green – phalloidin (f-Actin) 
Vitronectin coating resulted in an increase in cell attachment 19,604 ± 1,829 hMSCs per cm or a 
187% increase from regular sutures. There was a significant difference in cell attachment between the 
vitronectin coated suture and control microthreads sutures. Vitronectin effectively binds to fibrin and 
may have increased the amount of cell binding domains such as the RGD sequence (Figure 43) on the 
already ligand rich fibrin microthreads.80 The cell number on vitronectin coated sutures matches the 
number calculated as the theoretical maximum cellular attachment to a cm of suture (19,920). This 
suggests we may have reached the maximum cellular attachment onto sutures with the vitronectin 
coating but there appears to be barren areas allowing for further cellular attachment based on 
observations made via microscopy.  
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Figure 43:  Vitronectin structure, highlighting the fibrin binding sites (bottom) and the arginine-glycine-aspartic (RGD) acid 
ligand, binding sites for plasminogen activator inhibitor-1 (PAI-1), urokinase plasminogen activator receptor (uPAR), heparin 
and plasminogen (top) 
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Even with the increase in cellular attachment and seeding density on the vitronectin coated 
sutures the seeding efficiency is still low (approximately 40%) resulting in a waste of 60% during the 
seeding process. Cellular attachment to coated or control microthread sutures could be attributed to a 
select adherent subpopulation of hMSCs that contain binding domains for fibrin, poly-l-lysine, or 
vitronectin.96,97 If only a select population of cells adhere to the microthread sutures than cellular 
seeding efficiency corresponds to the percentage of adherent cells that exist in the general population.  
If this is true a possible way to increase the cellular attachment and seeding efficiency could be through 
the selection and expansion of those adherent cells. However if this is not the case cell seeding 
efficiency could be related to cell seeding density. Lower seeding densities could result in a similar cell 
attachment and number onto the sutures but a higher cell seeding efficiency. While higher seeding 
densities could result in a lower seeding efficiency as more cells will be wasted during seeding. 
The vitronectin coating did not appear to affect the hMSC phenotype however this is only based 
on qualitative visualization.  Prior work has shown that hMSCs seeded onto fibrin microthread sutures 
maintain their multipotency.13 As discussed earlier the coating of poly-l-lysine changes the morphology 
of hMSCs and could be a sign of a much larger change such as differentiation. Further tests similar to 
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those done by Proulx et al. must be done in order to assure that hMSCs seeded on coated sutures 
maintain their multipotency.  
6.1.2: Sub-Aim 2 - Extended Culture Time  
 It was our hypothesis that with dynamic seeding and increased culture time we will see an 
increased cell number as compared to the standard 24 hour seeding time, similar to the work done by 
Proulx et al. Sutures cultured for 48 hours of had a lower cell number (4,417±2,266 hMSCs per cm) or a 
35% decrease in cell number when compared to the sutures that were seeded for only 24 hours.   
These decreases in cell number may be a result of growing media toxicity over time associated 
with the high cell concentration in a relatively small volume of medium. After 24 hours, if anchorage 
dependent cells, such as hMSCs, have not attached, they may begin to undergo apoptosis.98 Following 
apoptosis, cells begin to shrink and release membrane bound apoptotic bodies. Due to the lack of 
phagocytic cells in vitro, apoptotic bodies remain in solution and eventually lose integrity and expel toxic 
and immunological material. 99,100 Dead or dying cells can release ‘danger signals’ and harmful cytokines 
into the media which could initiate the beginnings of apoptosis or necrosis of attached cells.101 
 The high cell concentrations can lead to the accumulation of waste products such as lactic acid, 
ammonia, and carbon dioxide could overcome the media’s buffering capacity, decrease the pH, stifle cell 
growth, and protein production.102,103 Macroscopic bubbles observed inside of the bioreactors could be 
attributed to the production of carbon dioxide from the cells, leakage from a faulty seal, or evaporation. 
If media were to evaporate from the tubes, the osmolality of the media would change. Whatever the 
mode of media loss, if an area of the thread was exposed it will begin to dry it would create an area with 
less than optimal cell survival conditions. The hostile environment in the bioreactor could attribute to a 
drop in cell number after the initial 24 hours. To verify this theory, further tests must be done.  
An added complication after 48 hours of incubation was the degradation of sutures, often the 
complete or partial degradation of the suture, or more commonly a break at the needle-suture 
interface. Negative controls which contained just culture medium did not show any signs of degradation 
or contamination. After seeding, the medium was negative for contamination after macro and 
microscopic visual assessment. It appears that given enough time the hMSCs will initiate the enzymatic 
breakdown of the fibrin microthreads. hMSCs possess the ability to activate the fibrinolytic proenzyme 
plasminogen, inhibit this activation and actively degrade fibrin gels in vitro.104 hMSCs have also been 
shown to secret matrix metalloproteinases.105,106 A potential method to overcome thread degradation is 
physical or chemical cross-linking the fibrin microthreads.12  Another potential method to prevent 
degradation and increase the cell viability is the removal of the seeded sutures from the bioreactor after 
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the initial 24 hours. The seeded sutures could then be placed in wells of fresh culture media for further 
incubation. Increased culture media volume could act as a “sink” or a buffer for the accumulation of 
waste products and enzymes.  While this method would protect the cells from harmful waste products 
the removal from the bioreactors and addition of media could potentially dislodge cells from the sutures 
further tests must be done to determine the outcome of this method.  
Coating the sutures with vitronectin not only aids in the cell attachment to the provisional fibrin 
matrix, but has also shown to have a role in fibrinolysis.80,107,108 Vitronectin contains binding sites for the 
different molecules that are involved in fibrinolysis including plasminogen, urokinase plasminogen 
activator receptor (uPAR), and  type 1 plasminogen activator inhibitor (PAI-1; Figure 43).80 PAI-1 is a 
direct inhibitor of the tissue plasminogen activator (tPA) and is found in two states, a non-inhibitory and 
an inhibitory form. The addition of vitronectin to fibrin increases the amount and duration of PAI-1 
binding resulting in a decrease of fibrinolysis in the presence of  tPA and plasminogen.107,108 The addition 
of vitronectin into our sutures could affect the in vitro and in vivo degradation rate. Further tests must 
be done to verify this hypothesis.       
6.1.3: Cellular Alignment  
To quantify cellular alignment we determined nuclear angle in comparison to individual 
microthreads. Nuclear alignment and elongation have been determined to be a robust measurement of 
overall cellular alignment and elongation.69,89,90,92,93 We showed that control sutures after 24 hour 
seeding had the lowest average angle, the most cells aligned along the threads, and the least nuclei 
considered circular. Poly-l-lysine had a lower average angle as compared to vitronectin and after 48 
hours of seeding on control sutures. Poly-l-lysine, vitronectin, and 48 hour seeding had equivalent 
aligned nuclei but poly-l-lysine had the most circular nuclei. As a control and to evaluate hMSC behavior 
on a topographically flat surface we used tissue culture plastic (TCP) which resulted in the highest 
average nuclear angle, the least aligned nuclei (using 0° as the direction of alignment), and the second 
most nuclei considered circular.  
During implantation we believe cells are subject to shear loading along the length of the 
suture.15 If a cell is spread out and aligned along the long axis of the suture it would also be aligned 
along the direction of shear during implantation. A low profile, elongated, and aligned cell may be more 
resistant to tissue forces as compared to a high profile, spherical, or unaligned cell (Figure 44). A low 
profile, elongated, and aligned cell will act as a streamline wedge resulting in less interaction with the 
tissue and less of a chance of shearing off of the suture. Our control sutures had the most aligned and 
elongated cells and the second most aligned and elongated cells were on the sutures after 48 hours of 
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culture. Based on our hypothesis, one would expect the cells on the control sutures to be more resistant 
to shear than those after 48 hour of culture but this is not the case. More cells detach from our control 
sutures than after 48 hours of culture. This circumstance might not be a function of alignment or 
elongation but rather overall cellular adhesion, increased quantity and quality of focal adhesions or the 
forces exerted on a cell during spinning versus implantation into tissue. A way to determine the role of 
cellular alignment and elongation in shear resistance would require subjecting the randomly oriented 
hMSCs seeded onto TCP to the in vitro shear assay.    
Cellular alignment is an important part of certain tissues overall function. The main purpose of 
the fibrin microthread sutures is to act a degradable scaffold for cellular delivery to specific areas of 
tissue. As stated previously, our control sutures had the most aligned cells while each modification 
resulted in varying degrees of cellular alignment. As a whole, cells aligned in the direction of our sutures 
as compared to cells placed on a topographically flat surface. If any suture type is implanted in the 
direction of overall tissue alignment then the cells delivered will already have a head start integrating 
into the aligned tissue as compared to the random orientation following any injection derived delivery 
method. 
Alignment of cells on the sutures was evaluated in relation to individual microthreads that make 
up each suture. This is due to that fact that cells will not respond to the macro-scale size of bundles or 
sutures but will be affected by the micro-scale interactions between threads and the individual threads 
themselves.70 Threads are twisted to create the bundle and then the bundle is twisted to create the 
suture, ultimately creating an intricate network of microthread interactions with varying angles. Better 
alignment of seeded cells might be achieved by eliminating the twisting of microthread and bundles 
when creating sutures and instead using parallel fibers.  
Cellular alignment on the sutures is not only dictated by the suture topography but also by cell 
to cell interactions and the seeding method. Pictures taken to evaluate cellular alignment did not 
discriminate between areas of high and low cell density. Areas of low cell density will have little to no 
cell to cell contact allowing cells to freely migrate, elongate, and align. The opposite will occur in areas 
of high cell density. High cell densities will result in increased cell to cell contact and the potential 
inhibition of alignment and elongation. Data obtained from this experiment characterizes how cells align 
and elongate when seeded with approximately 50,000 cells/cm of suture and could change with an 
alternate seeding density. Another aspect that could be affecting seeding densities is the seeding 
method and how cells are introduced in the bioreactor. Cells are injected at one end of the bioreactor 
and must travel 2 cm from the port to the end of the suture mode which could lead to cell attachment 
 72 
 
gradients.  Also, in theory the sutures are free floating in middle of the tube allowing all surfaces of the 
suture to be coated by cells. However many times the suture will settle and stick to one side of the 
bioreactor blocking a surface of the suture from being seeded and creating high cell densities on other 
areas of the suture. A method to secure the suture in the center of the tube could help prevent this 
uneven distribution. Further work should determine if a new seeding method will alter the seeding 
densities and cell to cell interactions will affect cell alignment and elongation. 
 
Figure 44: Schematic of forces on cells during implantation. More tissue (red arrows) interacts with unaligned and round cells 
(left) unlike aligned, low profile, and elongated cells (right).  
6.2: Specific Aim 2 
6.2.1: In Vitro Shear Load Model 
We hypothesized that cells were lost during implantation due to shear forces experienced by 
the cells as they were pulled through tissue.15 We attempted to simulate this force with a mechanical in 
vitro centrifugal adhesion assay similar to those developed to determine cellular adhesion force(Figure 
45).109,110 The exact numerical value for this shear force in situ is unknown so we explored a range of 
potentially relevant loads in vitro as might be due to different tissue densities and forces at which a 
surgeon will drive or pull a suture.  Spinning the control sutures at g10 resulted in 57% of cells remaining 
on the sutures similar to the 63% of cells remaining on the sutures and engrafting after experiencing the 
shear forces of implantation.15 
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Figure 45: Schematic for cell attachment after spinning. Seeded suture prior to spinning coated with cells (left). Spinning 
seeded sutures with the centrifugal shear model (center) results in cell loss for g10 (top right) and g50 (bottom right). 
6.2.2: Cell Adhesion  
The control and vitronectin coated sutures showed a trend of decreasing cell number with an 
increasing g-force.  Poly-l-lysine coated sutures had a relative decrease in cell number with increasing g-
force but the differences were not significant. It appeared that the few cells that attached to poly-l-
lysine coated sutures remained attached even after the exposure to g-forces. With additional culture 
time an increase in g-force did not affect the cell number on the sutures. After g50, there were still 98% 
of cells attached as compared to the unspun control suture after the traditional 24 hours seeding, 
suggesting that the additional incubation time increased the adhesion of cells onto the sutures. An 
increase in culture time could allow for the cells to develop higher quantities and stronger focal 
adhesions. The time could also allow for the alignment and creation of a stronger cytoskeleton. The 
exact reason for the increase in adhesion is unknown, further tests would need to be done to determine 
the reason.     
6.2.3: Potential Increase in Cell Delivery to Tissue and Clinical Implications 
After spinning with a force equivalent to g10, ploy-l-lysine had 70% less cells than the control 
sutures prior to spinning, while there is an increase of 103% with vitronectin sutures. After an increase 
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to g50 only 27% of cells remaining remain on the control sutures as compared to the unspun sutures. 
While ploy-l-lysine and vitronectin coated sutures resulted in a 67% and 21% decrease, respectively, 
when normalized to the control sutures prior to spinning. In terms of the coated sutures, vitronectin 
shows the most promise. While the rate of cell adhesion post-centrifugation did not increase, we were 
able to substantially increase initial cell number onto the sutures and in turn increase the absolute 
number of cells adherent post-centrifugation. Vitronectin coated sutures had nearly two times the 
amount of cells still attached after g10 as compared to the control sutures prior to spinning. Vitronectin 
had 3.5 times as many cells after g10 than the control sutures at g10.  After g50 the vitronectin coated 
sutures had a large drop in cells but it still had more cells attached as compared to the control sutures at 
g10.Poly-l-lysine was unaffected by the increased centrifugal force but had a lower initial and post-
centrifugation population numbers.  
Extending the culture on control sutures to 48 hours showed an insignificant reduction of cells 
prior to spinning and resulted in no cell loss at increasing g-force. Yet some sutures began to degrade 
and become physically compromised. To overcome this we suggest changing the seeding and culturing 
method.  Additionally, coating sutures with vitronectin not only results in nearly a threefold increase in 
cell attachment but as discussed previously could hinder degradation. Extending the culture time on 
vitronectin coated sutures could improve cellular delivery to tissue through higher cell numbers and 
shear resistant cells, ultimately leading to increased and even delivery of cells. Further tests should be 
done to evaluate the effectiveness of combining the two modifications including the in vitro shear 
model and in vivo implantation studies. 
Clinical Implications 
Advances in medicine have developed new therapies utilizing the delivery of exogenous cells to 
diseased tissues. Major obstacles in the effectiveness of these therapies are limitations imposed by 
current inefficient and poorly-localized cell delivery techniques. A delivery mechanism has been 
developed in order to increase the therapeutic response without the large waste in resources. Fibrin 
microthread sutures have shown the ability to efficiently deliver 63% of cells attached to the suture to 
the heart wall.15 With the current system used by Guyette et al. if a 2cm suture were implanted, 
approximately 7,500 cells will engraft.15 Based on human clinical trials and studies done in animal 
models, the implantation of a single suture used by Guyette et al. will result in a lower cell engraftment 
number compared to than those that saw a therapeutic response. 11,30,31,111 To reach therapeutic levels 
the amount of suture actually implanted or the number of sutures to be implanted must be increased. 
Our work has developed two modes to increase the cellular delivery to tissue. With the incorporation of 
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a vitronectin coating onto our sutures the cell number and seeding efficiency increases nearly threefold. 
By increasing the initial cell number on the sutures we will have increased the amount of cells available 
to engraft into the tissue after implantation. Another mode of increasing cellular delivery is to increase 
the engraftment rate. The implantation of the suture subjects cells to a shear force that attributes to 
detachment, a drop in engraftment rate and an uneven distribution. We have also shown that an 
increase in incubation time corresponds to an increase in cell adhesion to the fibrin microthread sutures. 
By increasing the cellular adhesion cells become more resistance to shear which prevents detachment, 
increases the engraftment rate, and evenly distributes cells. Independently the coating or increasing the 
incubation time will deliver more cells to the tissue compared to the current unmodified suture. By 
combining the two modes we will have the potential to not only increase the amount of available cells 
for delivery but also increase the engraftment rate. With the modifications the total amount of cells 
delivered with a single suture will approach the amount of cells that resulted in a therapeutic response. 
The implications for this enhancement could not only reduce the incidence of cardiovascular disease as 
a result of a myocardial infarction but could change the landscape of all cell based regenerative 
therapies. By increasing the efficiency of the delivery method more cells can be utilized and will engraft 
without the fear of waste and ultimately increase the effectiveness of the therapy and regeneration. 
6.3: Limitations and Future Work   
6.3.1: Limitations 
 Certain limitations were negotiated in this study. The first is dealing with the fibrin microthread 
sutures themselves. The entire fibrin microthread suture creation process is done by hand, creating 
variability from suture to suture particularly variability in thickness. To mitigate this issue, a single 
individual was assigned to making threads. Individual microthreads are stretched during creation and 
then during bundling they are twisted to create the thread construct. There can be different degrees of 
stretching and twisting creating differences in thickness, angles, and surface area of the sutures. 
Changes in surface area and twisting can ultimately lead to variability in cell attachment and how cells 
align. These areas of variability can be overcome with a fully automated system to create discrete 
microthreads, bundles, and sutures. 
 Another source of variability could come from cell culture and material – cell interactions. 
During the process of seeding sutures, cell concentrations are determined manually with a 
hemocytometer, creating opportunity for inaccurate counts. Precautions are taken in order to assure 
that samples taken for counting are a reflection of overall cell population. To seed the sutures 
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approximately 100µl of the cell suspension was injected into the bioreactor but due to the inaccuracies 
of manual syringe injection different volumes could have been dispensed. Further complicating the 
seeding is the settling of cells towards the bottom of the syringe, creating inaccurate cell concentrations. 
To overcome this problem the syringe contents were occasionally mixed. A new seeding method should 
be developed that will ensure accurate volumes and cell concentrations.     
 The material – cell interactions are complex especially when the interactions are xenographic in 
nature. Fibrin and thrombin were derived from bovine blood while the vitronectin and hMSCs were 
harvested from a human donor. If fibrin microthread scaffolds are to be used in the clinical setting 
materials should be changed to those harvested from humans. Human derived microthread scaffolds 
have not been created and the interaction between human derived cells and sutures are unknown. 
Human derived fibrin microthreads should be created and their interaction with human cells should be 
characterized.  
 Another limitation with these experiments is the use of fetal bovine serum as the primary media 
supplement in the cell growth media. Unsupplemented media such as Dulbecco’s Modified Eagle’s 
Media is a balanced salt solution that contains carbohydrates and amino acids. Yet it lacks nutrients and 
growth factors that promote cell growth and proliferation. The addition of serum is the standard to 
supplement medium with these necessary proteins and nutrients, most commonly the addition of fetal 
bovine serum. The exact composition of commercially available fetal bovine serum is unknown and 
differs from supplier to supplier, and lot to lot.112–114 Suppliers’ do attempt to define fetal bovine serum 
by testing osmolality, presence of endotoxins, and overall growth promoter concentration but the 
characterization of specific protein compositions is imprecise.112 Methods to test the presence and 
concentrations of individual proteins, vitamins, fatty acids, lipids, and growth factors are expensive and 
time consuming.112,114 The use of undefined medium creates an area of variability as the serum contains 
proteins both block binding sites and promote cell attachment at unknown concentrations.112 Fetal 
bovine serum also contains fibrinolytic precursors and inhibitors.112 The removal of these substances 
could change the cell attachment and degradation rate of the sutures while in culture. Further tests 
must be done with a serum free media or defined serum replacement media to better understand the 
interactions, seeding, and degradation rate of the hMSCs on regular and coated fibrin microthread 
sutures. 
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6.3.2: Future work 
 We have created improvements that could greatly increase the effectiveness of a delivery 
method for cellular therapies. Yet during the completion of work, a number of trends were identified 
that could lead to improved cell attachment and adhesion outcomes aside from those already explored. 
These areas for improvement relate to both the biological microthread suture and also the manner in 
which cells are introduced to it. In particular, the following would be readily achieved and worthy of 
additional research:  1) alternative coatings, 2) an improved seeding process, 3) a new bioreactor.  
Coating sutures is not limited to the two particular attachment promoters that were chosen. 
Fibrin has the ability to bind to growth factors, cytokines, and other ECM proteins that promote cell 
attachment and migration which will aid in the repopulation and regeneration of damaged tissues.21,59 
This tailorable function of the fibrin microthreads can be used not only to increase the attachment of 
hMSCs but can be optimized for any cell type that a researcher wishes to utilize. For example coating the 
sutures with an ECM protein similar to vitronectin such as fibronectin could be advantageous. Another 
method could incorporate a fibronectin/vitronectin dual coating in an attempt to match the in vivo 
provisional fibrin wound matrix.59,78,79 
Another way to increase cellular attachment as discussed previously is the manipulation of the 
seeding process.86–88 Our current method utilizes a continual rotation at 4 rpm. Some variables that can 
be changed from our current method are the rotation speed and pattern. The MACSmix™ rotator’s 
slowest speed is 4 rpm but the rotational speed has not been optimized to hMSCs. Changing the speed 
might allow more cells to settle on the sutures due to less mixing and agitation.  Changing the pattern of 
rotation could also change cell attachment. By using a dynamic/static rotational method cells would be 
allowed to settle and attach while the sutures were not rotating and then those that did not attach 
would be given the opportunity to attach to a different side of the suture after rotation. These methods 
will need to be evaluated not only for hMSCs but for cells that possess different attachment profiles.    
As previously described, the bioreactor design that is currently used could be effecting cellular 
attachment. Sutures are placed in a silicone tube much larger than the diameter of a suture. This allows 
cells to settle to the bottom of the tube and avoiding contact with the suture even during rotation. 
Using a smaller diameter tube would eliminate this “dead space” and cells will have more interactions 
with the suture. Another issue includes the amount of tubing required to hold the 100µm cell solution. 
There are areas of tubing and cell solution that do not contain suture. Any of these changes could 
potentially effect cellular attachment by increasing the interaction between the suture and the cells, 
further work must be done to determine the outcome of any of these changes.   
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Conclusion  
 We have shown that we can increase the cell attachment to biological microthread sutures with 
an extracellular matrix protein coating of vitronectin, increasing the seeding efficiency and cell number 
by nearly threefold. We have also shown that cellular adhesion increases to fibrin microthread sutures 
with additional culture time. The addition of vitronectin and further culture time to biological 
microthread sutures may increase both the cell attachment and cellular adhesion. Increasing both 
attachment and adhesion will lead to an increase in cellular delivery to diseased tissues, due to higher 
cell numbers and shear resistant cells. By increasing the effectiveness of the delivery method more cells 
will be delivered at one time and will reduce the amount of resources needed and increase the 
therapeutic effects of cellular therapies. 
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Appendices 
Appendix A: Fibrin Microthread Creation 
How to Make Threads 
Materials: 
 Silver pan 
 Syringe pump 
 1 aliquot fibrinogen - 70mg/ml  
 1 aliquot thrombin – 8U/200µl 
 10mM HEPES solution 
 2 - 1mL syringes 
 1 – 3ml syringe 
 1000mL graduated cylinder 
 Clear cup of warm water 
 Blue foam tube holder 
 40mM CaCl2 
 1000µl Micropipetter  
 2 sets of tweezers 
 Drying box  
 Latex gloves- wear at all times 
 Kimwipes 
 Extruding tube 
 Syringe connector 
 Syringe co-extruder  
Preparation: 
1. Rinse graduated cylinder with DI water. Pour into 500mL of 10mM HEPES solution the 
silver pan. 
2. Obtain 1 aliquot of Fibrinogen and 1 aliquot of Thrombin from the freezer. Also obtain 
40mM CaCl2 from fridge. Defrost them by placing them into the blue foam holder then 
into the water.  
3. Once completely defrosted, Add 850µL of 40mM CaCl2 into the thrombin, mix in 
vortexer.  
4. Label two 1ml syringes, one as T, and one as F. 
5. Using syringe appropriate withdraw thrombin and fibrinogen.  
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6. Remove all air bubbles from syringe. 
7. Balance the two syringes so that they contain the same amount of liquid. Make sure to 
tap out any air bubbles. 
Setting up Machine: 
1. Plug in syringe pump and turn on. Power switch is in the back of the machine. 
2. Make sure diameter is set to 4.699mm and the rate is set to 0.23 mL/min. 
3. Put the two syringes in the white co-extruder. 
                                                
 
 
 
 Make sure to use correct side with the matching syringe. 
4. Place syringes into syringe pump. 
 Lift black knob and slide the ends of the syringes under black bar, splitting the 
two syringes with the knob. Make sure syringe body flanges are inserted in to 
clamp. Release black knob. 
 Tighten syringe clamp using the silver nuts. 
 Use the small white syringe connector to keep the syringe plungers together. 
Attach to the end of the plunger.  
 
 
 
 
 
This part goes in clamp 
Connecter goes here 
5. Make syringe pump block flush with the syringe connector.  
 To release Half-nut, Push down black button and pinch white piece   
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6. Attach extruding tube to the white co-extruder. Do not let the tube go into the HEPES 
yet. 
Making Threads: 
1. Press start on the machine. 
2. Wait for ALL the air bubbles to pass through the extruding tube. Use a Kimwipe to 
collect anything that comes out while air bubbles are passing through. 
3. Once there is a constant flow, start making the threads.  
Hold extruding tube ≈ 1 inch from the end. Drag end of tube horizontally along the 
bottom of the silver pan filled with 10mM HEPES. Move the tube from the left side of 
the pan to right side at a constant rate. At the end of one thread move quickly bring the 
end of the tube back to the left side of the pan, move ≈ 1 inch down and begin a new 
thread. Repeat until you cannot make anymore. *Make sure the end of the tube is clean 
and free of fibrin debris, wipe clean if needed  
4. Do Not Overlap Threads! 
5. Turn off machine once you are done. 
Clean Up Part 1: 
1. Immediately clean tube. Fill a 3ml syringes with water and flush extruding tube with 
water. Remove syringe from extruding tube, withdraw syringe with just air and blow air 
through extruding tube with syringe. Repeat with white co-extruder. 
2. Throw away any used materials into the proper trash receptacle. 
Transferring Threads: 
1. Use the two sets of tweezers to take the threads out of the pan.  
 Grab each end of the thread with the tweezers 
 
 
 
 
 
 Move right hand counterclockwise and left hand clockwise so you can pick up 
the thread.  
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 Make sure not to pull too fast and to keep threads in the HEPES as long as possible. 
2. Transfer the threads to the cardboard box. Secure one side to the box and stretch the 
thread. Secure the middle of the stretched out thread to the box. Cut the thread in half 
then stretch the remaining half over the box. One extruded thread should produce two 
threads   
3. Repeat this for all threads. Leave threads out to dry. 
Clean Up Part 2: 
1. Pour HEPES down the drain and rinse off pan. Dry the pan with paper towel. 
2. Put tweezers, pan, syringe pump, and cup back into the drawer. Put away any other 
items. 
3. Dispose of any other used items in the appropriate receptacle.  
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Appendix B: Seeding Fibrin Microthread Biological Suture 
Materials: 
 Sterile thread-bundle in Bioreactor 
 Sterile PBS 
 Sterile 1 mL syringe (3) 
 Cell Suspension (100,000 cells/100 µL) 
 50 mL conical tube 
Procedure: 
1. Use a sterile syringe to inject sterile PBS into bioreactor (by attaching syringe to the already 
inserted 27G needle). 
2. Ensure all bubbles are eliminated from the bioreactor. 
3. Attach slide clamp and remove/discard syringe. (Keep syringe needle in the bioreactor). 
4. Allow 20 min for hydration 
5. While bundle hydrates prepare cell suspension according to cell passaging protocol 
6. Use new syringe to expel all sterile PBS from the bioreactor before seeding. For this, remove the 
slide clamp at the end opposite to the needle, draw air into a new sterile syringe and push the 
air into the bioreactor to expel all the PBS.  
7. Use a new syringe (1 cc maximum) to inject cell suspension (100,000 cells / 100 µL) into the 
bioreactor. For this, hold the bioreactor such that the open end of the bioreactor (one without 
slide clamp) remains elevated such that the cell suspension doesn’t spill out while being 
injected.  After 100 µL of cell suspension is injected into the bioreactor, close the end opposite 
the needle by sliding the clamp onto the tubing. 
8. After injecting the cell suspension and adding the slide clamp, remove the 27G needle from the 
bioreactor. 
9. Place the bioreactor into a gas permeable 50 mL conical tube. 
10. Place the bioreactor into the MACSmix tube rotator and rotate at 4 RPM (lowest setting) for 24 
hours. 
 
 
 91 
 
Appendix C: Human Mesenchymal Stem Cell Culture  
General Culture and Changing Media 
Preparation 
1. Wash your hands when you enter the lab. General lab safety measure. 
2. Put media in the water bath. 
Verifying cells are healthy 
3. Take cell culture flask out of the incubator. Take care not to tilt the flask, the media should not 
enter the neck of the flask. 
4. Inspect the media visually: 
a. Color: - should be dark pinkish red. If yellow / yellowish orange – immediate action – 
change media / discard cells. 
b. Transparency: Cells in good health show transparent, clear media. If cloudy  sign of 
contamination / aging / dying cell culture. 
5. Microscopic examination: Examine the cell culture flask under an inverted microscope; first 
under low magnification (usually 4x) and then under medium magnification (usually 10x).  
Things to look for: 
a. Floating cells (dead or unhealthy), cellular debris, bacteria or fungi, other unidentifiable 
debris  signs of unhealthy culture. Immediate action necessary: 
i. If contaminated – suction out all media into waste, spray the inside of the flask 
with alcohol, suction the alcohol, and then discard in biohazard. 
ii. If unhealthy, but not contaminated – change media with fresh, warm culture 
media. Examine again after 24 hours and feed with fresh media again. 
b. If cells are nicely spread out (adhered), look for vacuoles within the cells. Presence of 
too many vacuoles is an indication that the media needs to be changed. 
c. Confluence of culture  Look in at least 5 locations within the flask, usually four corners 
and the center. Calculate confluence and note it down. For 80 – 100 % confluence – 
passage the cells. For cultures older than 14 days – passage the cells, irrespective of 
confluence. For the rest, replace old media with fresh media (which is referred to as 
“feeding the cells.”) 
Preparing the Hood 
6. Take cell culture cart from lab bench area to cell culture room, along with 1000 µL micropipette 
/ pipette aid (depending upon flask size), corresponding sterile pipette tips and other items as 
necessary. 
7. Put gloves on, spray hands with alcohol. (do this every time something unclean/not sterile is 
touched) 
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8. Spray the inside of the laminar flow hood (working surface and bottom third of the side walls) 
and wipe down. Make sure to clean the vacuum line also, by spraying both the outside and 
inside of the tube with the vacuum turned on. 
9. Spray and wipe all objects that you intend to take inside the laminar flow hood. Be careful not to 
spray the cap of the flasks the cells are in. 
10. Attach the Pasteur pipette on the vacuum tube and place it in a manner that the tip doesn’t 
touch any object while you work in the hood. Set up all other items in the hood. 
11. Bring warm media from the water bath and the cells from the incubator. WIPE DOWN MEDIA 
AND CELL CULTURE FLASKS THOROUGHLY WITH ALCOHOL, as the water bath and incubator are 
common sources of contamination. 
Feeding 
12. Unscrew the flask cap and place it in a way that its inner side doesn’t touch anything while 
you’re working on the flask. Tilt the flask so as to accumulate the media in one corner of the 
closed end of the flask (opposite the open end through which you insert the Pasteur pipette).  
13. Insert the Pasteur pipette slowly taking care not to touch any inner walls of the flask. Suction 
the media out from the cell culture flask taking care not to touch the bottom surface, where the 
cells are attached. 
14. Add 4mL (or required volume) of fresh, sterile, warmed media with a micropipette/pipette. Take 
care not to touch any part of the flask (especially inner surface of the neck) with the pipette tip 
while dispensing media. If the tip touches any surface accidentally, discard the tip and use a 
fresh one. It’s important not to contaminate the stock solution of media, therefore use only a 
fresh, sterile tip to aspirate media from its storage bottle. 
15. Cap the cell culture flask immediately after media is added screw the cap on tight. Return the 
cell culture flask to the incubator. (As a general rule, try keeping the cells out of the incubator 
for as short a duration as possible: mammalian cells like to be in a 37oC-environment – that of 
the incubator). 
Clean-up 
16. Cap all bottles (media, sterile PBS, other) tightly, remove all objects from the laminar flow hood. 
Spray the inside of the laminar flow hood with alcohol, and wipe down. Be sure to clean the 
vacuum line as well.  
17. Switch off the light of the laminar flow hood. (DO NOT turn on the UV light unless explicitly 
instructed to do so). 
18. Return all items to their designated storage places.  
19. Update Cell Culture inventory / inform your mentor. 
Passaging Cells 
1. Place media and trypsin in water bath and remove hemocytometer from alcohol bath to dry 
2. Remove flask or petri dish and verify cell viability and confluence with scope. Place in bio-safety 
cabinet 
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3. Aspirate media off cells with a sterile Pasteur pipette 
4. Wash cells with DPBS by gently rocking back and forth for 1 minute  
5. Aspirate off DPBS 
6. Add Trypsin, place back into incubator allow to sit for 5 minutes 
7. Remove from incubator and confirm cell detachment with scope (detached cell will float freely 
and appear round) 
8. Add equal amount of cell culture media ad trypsin to flask or petri dish (FBS deactivates trypsin)  
9. Pipette content out of flask of petri dish and place into sterile 15 mL conical tube  
10. Centrifuge the 15 mL conical tube for 5 min @1000 rpm (balance centrifuge) 
11. Spray down conical tube before reintroducing into safety cabinet, aspirate off supernatant but 
do not disrupt the cell pellet at the bottom. 
12. Re-suspend the pellet with a known amount of media (between 0.5-10mL, depends on cell 
number and confluence) 
13. Triturate the solution to ensure homogeneous solution 
14. Remove 10µL of cell suspension and add to 10µL trypan blue stain (5µL stock trypan blue stain, 
5µL PBS) 
15. Triturate and load 10µL of cells and trypan blue solution into each side of hemocytometer. 
16. Count 5 boxes in each side of the hemocytometer for a total of 10 boxes  
17. Calculate cell number with the following equation  
               
                  
                                                     
18. Seed hMSCs at a concentration of ≈7000 hMSCs per cm2 on standard tissue culture plastic 
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Appendix D: Vitronectin Immunohistochemistry Staining 
-be aware of light sensitive materials 
1. Primary - mouse monoclonal anti-vitronectin (located in the freezer) 1:100 with 1% BSA-leave in 
walk in fridge overnight 
2. 3 washes in PBS 5 minutes each 
3. 2.5:100 rabbit anti-mouse AlexaFlour 488 : 1% BSA with at least 100   of solution per tissue 
section-leave for one hour room temperature 
4. 3 washes in PBS 5 minutes each 
5. Coverslip 
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Appendix E: Fluorescent Staining of Seeded Sutures 
1. Rinse in DPBS 
2. Fix in 4% Paraformaldehyde in PBS for – 10 min 
3. Rinse with PBS – 2x 
4. 0.25% Triton X – 10 min 
5. Rinse with PBS – 2x 
6. Block with 1% BSA – 30 min 
7. Phalloidin in PBS – 30 min  stain f-actin – green 
8. Rinse with PBS – 2x Block with 1% BSA – 3x – 5 min each 
9. Hoechst – 3 min                                           stain nucleus – Blue 
10. Rinse with PBS – 2x 
11. Add spacers 
12. Seal with Cytoseal & 25x25mm cover slip 
13. Air dry, store in freezer when done 
Dilution   PBS 
BSA  40 μL in  3,960 μL 
Phalloidin 50 μL in  1,950 μL 
Hoechst 0.5 μL in 3,000 μL 
Triton  10 μL in  3990 μL 
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Appendix F: CyQUANT DNA Assay Protocol   
Materials 
 Molecular Probes/Invitrogen #C7026 
 Lysis buffer only #C7027 
 96 well plate 
Dilutions 
 1 mL lysis buffer in 19 mL diH2O (1x) 
 50 μL GR into 20 mL 1x lysis buffer 
Procedure 
1. Using older passage-cells, trypsinize and create cell suspension of 12,000 cells/100 μL – using/saving 
1mL of suspension           
Note: can change cell concentrations if using/counting larger number of cells 
2. Spin cell suspension down @ 2,000 rpm for 5 min 
3. Remove as much media as possible w/o disturbing cell pellet 
4. Add 500 μL D PBS and spin again @ 2,000 rpm for 5 min 
5. Remove 400 μL 
6. Freeze at -80°C for at least 1 hour, can store up to 4 weeks at -80°C 
7. In 96-well plate, place 100 μL of CyQUANT dye/lysis buffer in wells B-H, 1-4. Add additional 100 μL of 
straight CyQUANT buffer into H1-H4 
8. After removing from freezer, allow to reach room temp     
 *do not place in water bath, lightly vortex 
9. When thawing is complete, add 900 μL of CyQUANT buffer to standard curve (will be brought up to 
1000 μL) lightly vortex 
10. Place 200 μL of standard curve to wells A1-A4 
11. Bring 100 μL from A wells down into B, mix thoroughly, using same tip bring B to C and so on until G. 
H wells have No standard curve (this is blank). In A1-A4 add 100 μL of straight CyQUANT buffer 
12. Add 100 μL of CyQUANT buffer to A1-G4 
13. Preparation of sample for analysis  
13.1. After seeding and incubating, when ready to count, remove material from bioreactor 
and rinse in DPBS 
13.2. Place in 500 μL DPBS, spin @ 2,000 rpm for 5 min 
13.3. Remove 400 μL of DPBS 
13.4. Place in -80°C for at least 1 hour, can store up to 4 weeks 
13.5. Remove from freezer and allow to thaw at room temperature 
13.6. Add 400 μL of CyQUANT lysis buffer 
13.7. Lightly vortex 
13.8. Remove material from sample; place on slide for staining to confirm cell removal 
13.9. Pipette out 100 μL into 4 wells on 96 well plate (leaving 100 μL) 
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13.10. Once complete w/ standard curve and all samples, degas to remove bubbles 
14. Place in vacuum to degas 
15. Run on plate reader (480nm excitation, 520nm absorption) 
 
Note: 
Samples will saturate after 5 minutes of light exposure; work fast 
Should be 200 μL in all well of standard curve, if not add CyQUANT buffer until 200 μL is reached 
 
Calculations 
1. Read on plate reader 
2. Place data in Excel 
3. Calculate average, correlation coefficient, slope, and x-intercept of standard curve 
4. Take average of 4 samples, multiply by 5 (for 500 μL) 
5. Value for sample = (Average – y-intercept)/slope 
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Appendix G: Nuclear Alignment and Elongation Quantification 
1. Take 20 x Hoechst image 
2. Open in Image J 
3. Crop out- out of focus part 
4. Split channels: Image-color-split channels 
5. Delete all channels but the blue channel 
6. Threshold the blue channel: Image-adjust-threshold 
a. Set Parameters-Default-Red Dark background 
7. Apply 
8. Set Scale:  Analyze-Set Scale 
a. 20X Image Distance in Pixels = 376 
i. Known Distance = 100 
ii. Pixel AR = 1.0 
iii. Unit of Length = µm 
1. OK 
9. Set Measure: Analyze-Set Measurements 
10. Area 
11. Fit Ellipse 
i. All Other uncheck  
12. Particles: Analyze-Analyze Particles 
i. Size (µm^2) = 20-400 
ii. Circularity = 0-1 
iii. Show: Select ellipses 
13. Display Results 
14. Clear Results 
15. Exclude on Edges 
16. Include Holes 
a. Save File (will save as a .xls) file name = picture label  
b. Open in excel- Adjust A~ 90°  = If (Θ>90°, Θ 180°, Θ) 
1. Elongation = Major/Minor 
2. Measure thread angle using Angle tool 
Angle to Thread If (Θc>Θ 
3. t, Θc-Θt, Θt-Θc) 
c. Save file as a .xlsx  
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Appendix H: Raw Data 
CyQUANT Data 
005 
 
007-008 
 
 
 
Average Corr CoeffSlope Intercept
12000 137689 175882 136949 151425 150486 0.995109 12.76432 1107.497
6000 100153 83418 89531 83471 89143
3000 32173 15866 43868 40227 33034
1500 12082 15000 22811 21012 17726
750 9130 7976 11133 12219 10115
375 4864 4428 6925 7321 5885
187.5 3937 3422 4561 5028 4237
0 2200 2152 2137 2251 2185
Average Average *5 on thread
blank 3120 3031 3482 3120 3188 15941.25 1162.127
g-0 40792 40004 39489 43990 41069 205343.8 16000.56 14838.44
average Corr coeff slope intercept
12000 133512 139804 135158 141489 137491 0.997618 11.26743 5274.798
6000 69867 75484 81465 75886 75676
3000 50232 43610 43522 43155 45130
1500 23502 22020 26140 23885 23887
750 13039 10514 14605 13813 12993
375 7734 6579 8128 8358 7700
187.5 5737 5663 5261 5244 5476
0 2031 2040 2487 2052 2153
average Ave x 5
blank 4121 3002 3173 3182 3370 16847.5 1027.094
007 g-0 1 15951 16762 16019 16851 16396 81978.75 6807.583 5780.49
007 g-15 1 16446 17664 16431 17371 16978 84890 7065.961 6038.867
007 g-15 2 11025 11961 10740 9589 10829 54143.75 4337.188 3310.095
007 g-25 1 10634 11001 10296 11108 10760 53798.75 4306.569 3279.475
007 g-25 2 13969 14344 12829 13877 13755 68773.75 5635.621 4608.528
008 g-0 1 54287 57996 55547 53848 55420 277097.5 24124.65 23097.55
008 g-0 2 29735 30958 28886 31296 30219 151093.8 12941.64 11914.54
008 g-50 1 22243 22277 22124 22349 22248 111241.3 9404.671 8377.578
008 g-50 2 18818 17788 18443 18334 18346 91728.75 7672.91 6645.816
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010 
 
012 
 
 
 
 
 
average corr coeff slope Intercept
12000 136314 148109 150752 155734 147727 0.998598 12.13013 4952.687
6000 81669 83598 75559 85128 81489
3000 42699 44578 41580 47704 44140
1500 19744 24359 28281 27359 24936
750 18119 12870 13909 15986 15221
375 5898 7875 7759 9647 7795
187.5 4598 4831 4595 6409 5108
0 2141 2066 2107 1904 2055
average average*5
neg blank 3369 3325 3363 3296 3338 16691.25 967.7194
neg g-0 17796 18500 19333 19780 18852 94261.25 7362.539 6394.819
average corr coeff Slope Intercept
12000 150578 146947 146353 156394 150068 0.99224 12.56245 7003.843
6000 86683 102393 97728 91121 94481
3000 50965 48068 51001 54338 51093
1500 28071 27113 27478 28525 27797
750 15725 15755 15459 15265 15551
375 8728 8126 8848 9377 8770
187.5 5371 5477 5298 5016 5291
0 2040 2110 2251 2094 2124
average average*5
neg blank 2771 2530 2894 2699 2724 13617.5 526.4625
poly blank 3468 3874 4531 3802 3919 19593.75 1002.186
neg g-0 52401 56249 55410 54392 54613 273065 21179.09 20652.63
 101 
 
013 
 
014 
 
 
 
 
 
 
 
average corr coeff Slope Intercept
12000 175056 160178 181596 186780 175903 0.998467 14.59033 4530.334
6000 92319 100015 93541 102485 97090
3000 55906 55022 50826 52382 53534
1500 27484 25352 26809 26737 26596
750 14435 13823 15816 14516 14648
375 9101 8695 8256 8613 8666
187.5 4553 5223 5050 5462 5072
0 2221 2173 2127 2148 2167
average Average*5
neg blank 3745 2781 2765 2914 3051 15256.25 735.1385
poly blank 2878 2831 2807 2710 2807 14032.5 651.2645
neg g-0 55282 56221 55645 57749 56224 281121.3 18957.13 18222
average corr coeff Slope Intercept
12000 174268 178813 184904 181372 179839 0.998681 14.946 4088.956
6000 107255 100005 98332 95524 100279
3000 59522 54137 53513 31097 49567
1500 31048 28794 27938 26415 28549
750 17622 13791 14399 16412 15556
375 7911 7601 7263 8684 7865
187.5 5228 4951 4700 5148 5007
0 1973 1934 1915 1984 1952
average average*5 on thread
neg blank 2332 2337 2458 2510 2409 12046.25 532.4029
poly blank 2991 4119 2975 2917 3251 16252.5 813.8328
neg g-0 17498 21891 21412 22374 20794 103968.8 6682.711 6150.308
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016 
 
017-018 
 
 
 
 
 
average corr coeff Slope Intercept
12000 143374 152924 169095 191710 164276 0.995861 13.71859 5,741
6000 91642 89396 101035 108303 97594
3000 45717 45382 53355 63179 51908
1500 23919 26238 28629 34761 28387
750 14142 12002 16089 18338 15143
375 7947 8094 6214 9335 7898
187.5 5071 4854 6586 5494 5501
0 1901 1904 1911 1882 1900
 
016 neg blank 3096 3291 3217 2778 3096 15477.5 709.6962
016 poly blank 2698 2444 2660 2599 2600 13001.25 529.193
016 neg g-0 26165 27425 27695 30055 27835 139175 9726.473 9,017
average corr Coeff Slope Intercept
12000 177627 175768 182826 192035 182064 0.997944 15.1917 4571.001
6000 101608 104954 105038 102836 103609
3000 55635 52905 53629 54111 54070
1500 26463 28891 26837 27663 27464
750 14212 15680 15521 15738 15288
375 8780 8375 8849 8224 8557
187.5 5553 5151 4898 5144 5187
0 1920 2142 2154 2114 2083
average Average*5
017 neg blank 2797 2837 2850 3276 2940 14700 666.7458
017 poly blank 2390 2396 2541 2683 2503 12512.5 522.7526
017 neg g-0 55177 57110 57593 53168 55762 278810 18051.9 17385.16
018 blank 3559 3302 3092 3277 3308 16537.5 787.7
018 g-0 29028 30417 31761 31825 30758 153788.8 9822.324 9034.624
 103 
 
019-021 
 
 
 
 
 
 
 
 
average Corr CoeffSlope Intercept
12000 181157 175444 174406 174996 176501 0.997131 14.71958 5353.244
6000 102992 104244 102197 100632 102516
3000 53033 54306 52704 55109 53788
1500 27278 27919 30046 29286 28632
750 13887 15581 16697 15900 15516
375 8846 9013 8760 9623 9061
187.5 4921 5405 5220 5950 5374
0 1919 1991 1944 1938 1948
average Avg*5 on thread
019 blank 3295 3055 3205 3348 3226 16128.75 732.0524
019 g-0 1 40930 42579 41542 42314 41841 209206.3 13849.1 13117.05
019 g-0 2 46284 46925 46999 46107 46579 232893.8 15458.35 14726.3
019 g-10 1 18174 17369 18532 17645 17930 89650 5726.844 4994.792
019 g-10 2 16597 14972 16978 15760 16077 80383.75 5097.326 4365.273
019 g-10 3 32043 32846 35269 33934 33523 167615 11023.53 10291.48
019 g-10 4 21841 22862 23546 23239 22872 114360 7405.561 6673.508
021 blank 2939 3161 3195 3118 3103 15516.25 690.4412
021 g-0 1 51141 51469 53931 54264 52701 263506.3 17538.07 16847.63
021 g-0 2 56366 55425 56444 53004 55310 276548.8 18424.13 17733.69
021 g-50 1 32426 33088 34290 33138 33236 166177.5 10925.87 10235.43
021 g-50 2 14863 13878 15016 14816 14643 73216.25 4610.389 3919.948
021 g-50 3 56972 57625 57870 58301 57692 288460 19233.34 18542.9
021 g-50 4 7271 8942 8430 7849 8123 40615 2395.568 1705.127
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022-023 
 
 
 
 
 
 
 
 
 
 
average Corr CoeffSlope Intercept
12000 159600 171125 177958 168819 169376 0.996594 14.10725 5745.993
6000 109756 98085 97635 91484 99240
3000 55615 52458 49692 52455 52555
1500 37475 27522 26023 25117 29034
750 16278 15056 15202 16407 15736
375 8394 8370 8107 9821 8673
187.5 5664 5748 5390 5297 5525
0 1873 1879 1374 1908 1759
average Avg * 5 
022 blank 2387 2368 2504 2627 2472 12357.5 468.6603
022 g-0 1 111071 111632 106407 102557 107917 539583.8 37841.39 37372.73
022 g-0 2 4797 4575 5335 4242 4737 23686.25 1271.705 803.0447
022 g-10 1 42856 42403 42513 43900 42918 214590 14804.02 14335.36
022 g-10 2 34598 32511 33496 34409 33754 168767.5 11555.87 11087.21
022 g-10 3 23976 24249 19668 22404 22574 112871.3 7593.633 7124.973
022 g-10 4 13838 14287 14074 14359 14140 70697.5 4604.124 4135.463
019 1 5542 5776 5577 5682 5644 28221.25 1593.171
023 blank 2740 3083 2736 2759 2830 14147.5 595.5455
023 g-0 1 43590 45947 43531 45635 44676 223378.8 15427.02 14831.47
023 g-0 2 23951 26741 26860 26777 26082 130411.3 8836.966 8241.421
023 g-50 1 4421 4518 4219 4810 4492 22460 1184.782 589.2362
023 g-50 2 8780 8655 8703 10750 9222 46110 2861.225 2265.68
023 g-50 3 17983 17509 16442 15906 16960 84800 5603.787 5008.242
023 g-50 4 7792 7535 7468 8718 7878 39391.25 2384.963 1789.417
 105 
 
024-025 
 
 
 
 
 
 
 
 
 
 
 
 
average corr coeff Slope Intercept
12000 158063 159461 163530 160304 160340 0.999192 13.2594158 3684.645
6000 87118 87453 84934 86688 86548
3000 48574 46216 45165 46978 46733
1500 24765 24640 24187 22735 24082
750 13968 13055 12757 13490 13318
375 7020 8302 7851 6985 7540
187.5 4445 4647 4709 5223 4756
0 1597 1991 1961 2056 1901
AVG*5
024 Poly blank 2287 2386 2853 2777 2576 12878.75 693.4019551
024 neg blank 16617 20260 2915 2916 2916 14577.5 821.5184593
024 neg g-0 31826 29793 31568 17882 31062 155311.7 11435.42248 10613.9
014 poly g-0 1 35021 35594 38890 35885 36348 181737.5 13428.40873 12735.01
024 poly g-0 2 24734 29320 25323 24578 25989 129943.8 9522.222303 8828.82
024 poly g-0 3 56075 56062 58201 51728 55517 277582.5 20656.85691 19963.45
024 poly g-0 4 14068 14285 15066 13301 14180 70900 5069.254623 4375.853
024 poly g-0 5 20358 19139 18368 18915 19195 95975 6960.363582 6266.962
025 blnk neg 2516 2592 2552 3195 2714 13568.75 745.4404469
025 poly blank 3194 2891 2563 2622 2818 14087.5 784.5635884
025 neg g-0 77795 82609 79725 76756 79221 396106.3 29595.69341 28850.25
o25 poly g-0 12774 10759 11912 12444 11972 59861.25 4236.733027 3452.169
025 poly g-10 1 4253 4953 5150 5376 4933 24665 1582.298584 797.735
025 poly g-10 2 21313 22603 20395 19559 20968 104837.5 7628.756528 6844.193
025 poly g-10 3 3801 4339 4088 4160 4097 20485 1267.050909 482.4873
(AVG*5-
Intercept)/ 
SLOPE
On 
Thread
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026-027 
 
 
 
 
 
 
 
 
 
 
 
 
average Corr Coeff Slope Intercept slope avg
12000 27001 25477 26189 25526 26048 0.999127 1.9579923 2819.445 13.69327019
6000 14539 15326 14936 14694 14874 Intercept  AVG
3000 9262 8671 8750 9779 9116 5,190
1500 5820 5073 6638 6031 5891 poly blank avg
750 4149 4179 3602 4419 4087 793.118275
375 3697 3145 5435 3346 3906
187.5 2916 2711 2616 2760 2751
0 2713 2388 2448 2485 2509
AVG*5 
026 poly g-50 3 20091 18212 18443 18212 18740 93697.5 6463.6106 5562.221
026 poly g-50 2 17898 18024 17994 17543 17865 89323.75 6144.2019 5242.813
026 poly g-50 1 24219 26540 27551 29107 26854 134271.3 9426.6538 8525.264
026 poly g-0 9370 9861 9982 9544 9689 48446.25 3158.9764 2257.587
026 neg g-0 56605 55302 49869 55180 54239 271195 19426 18797.1
026 poly blank 3969 3049 3371 3637 3507 17532.5 901.38928
026 neg blank 2666 2731 2807 2837 2760 13801.25 628.90141
027 poly g-10 3 1751 1633 1694 1792 1718 8587.5 248.14868 4779.48 3986.362162
027 poly g-10 2 14726 12709 16284 12790 14127 70636.25 4779.4804 3024.33 2231.211663
027 poly g-10 1 9867 9349 9520 8546 9321 46602.5 3024.3299 5298.44 4505.321469
027 poly g-0 15451 15443 16220 15080 15549 77742.5 5298.4397 5428.157 4635.038474
027 neg g-0 14884 15863 15897 16971 15904 79518.75 5428.1567 7771.096 7129.505857
027 poly blank 22475 21351 22155 23300 22320 111601.3 7771.096
027 neg blank 2923 2655 2646 2956 2795 13975 641.59013
(AVG*5-
Intercept)
/ SLOPE
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028-029 
 
 
 
 
 
 
 
 
 
 
average Corr Coeff Slope Intercept
12000 170886 179871 175547 176785 175772 0.988956 14.71447 9811.88
6000 117013 111404 113974 114233 114156
3000 69201 60500 61077 63504 63571
1500 38039 36165 35740 33386 35833
750 19448 19662 19130 19510 19438
375 11544 11521 10935 10464 11116
187.5 6593 6519 6382 7009 6626
0 2049 2204 2141 3098 2373
AVG*5 
028 neg blank 3700 4130 4542 3805 4044 20221.25 707.4236
028 poly blank 3308 2903 2876 3259 3087 15432.5 381.9787
028 neg g-0 90162 95011 98401 94973 94637 473183.8 31490.89 31,109      
028 poly g-0 89864 94286 93452 91281 92221 461103.8 30669.93 29,963      
028 poly g-10 1 29763 30149 28626 31768 30077 150382.5 9553.22 8,846         
028 poly g-10 2 9261 9020 9550 9295 9282 46407.5 2487.049 1,780         
028 poly g-10 3 13475 12629 13021 12831 12989 64945 3746.863 3,039         
029 neg blank 3050 2900 3180 2893 3006 15028.75 354.5398
029 poly blank 2813 2780 2992 2707 2823 14115 292.441
029 neg g-0 17652 20318 18265 19108 18836 94178.75 5733.597 5,379         
029 poly g-0 26818 28429 28308 28501 28014 140070 8852.38 8,560         
029 poly g-50 1 7573 8197 7823 8045 7910 39547.5 2020.841 1,728         
029 poly g-50 2 12416 12291 12784 13752 12811 64053.75 3686.293 3,394         
029 poly g-50 3 10616 8715 10203 8673 9552 47758.75 2578.88 2,286         
(AVG*5-
Intercept
)/ SLOPE On Thread
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037-038 
 
 
 
 
 
 
 
 
 
average Corr Coeff Slope Intercept
12000 164235 174085 170542 165287 168537 0.999281 13.82239 4969.49
6000 86893 91585 92219 92564 90815
3000 51617 48754 49077 47786 49309
1500 27875 26086 28150 27109 27305
750 15282 14912 15135 14945 15069
375 8827 8867 9131 9114 8985
187.5 6287 5823 6955 6111 6294
0 2505 2502 2818 2528 2588
AVG*5 
037 vit blank 4962 5699 4865 5581 5277 26383.75 1549.245
037 cont blank 5007 6584 5319 5559 5617 28086.25 1672.415
037 g-0 control 85618 88169 88736 89394 87979 439896.3 31465.39 29,793    
037 vit g-0 1 128726 141548 129519 141033 135207 676032.5 48549 47,000    
030 vit g-0 2 87801 86492 89546 89008 88212 441058.8 31549.49 30,000    
037 vit g-10 1 76005 78097 78806 78692 77900 389500 27819.4 26,270    
037 vit g-10 2 166414 152884 152886 154991 156794 783968.8 56357.8 54,809    
037 vit g-10 3 107158 104243 115148 113001 109888 549437.5 39390.3 37,718    
038 vit blank 3484 3362 3357 3844 3512 17558.75 910.7878
038 cont blank 3262 2937 3002 2852 3013 15066.25 730.4644
038 control 7175 7352 6601 6947 7019 35093.75 2179.382 1,449      
038 vit g-0 1 95112 92674 93531 98491 94952 474760 33987.65 33,077    
038 vit g-0 2 91830 90507 98169 92885 93348 466738.8 33407.35 32,497    
038 vit g-50 1 28867 28972 29619 27560 28755 143772.5 10041.9 9,131      
038 vit g-50 2 8961 9795 10420 9627 9701 48503.75 3149.547 2,239      
038 vit g-50 3 20456 20295 21329 21207 20822 104108.8 7172.369 6,262      
(AVG*5-
Intercept
)/ SLOPE
On 
Thread
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039-040 
 
 
 
 
 
 
 
 
 
average Corr Coeff Slope Intercept
12000 153844 169282 164132 163933 162798 0.998044 13.46603 5260.68
6000 98167 92115 87703 91894 92470
3000 48851 47827 49331 48884 48723
1500 27530 26188 26443 26251 26603
750 14829 14131 20328 14574 15966
375 8479 7865 8914 8290 8387
187.5 5281 5267 5558 5323 5357
0 2370 2370 2433 2594 2442
AVG*5 
039-blank 3144 3570 3272 3264 3313 16562.5 839.2836
039-vit-blank 4323 3964 4196 4106 4147 20736.25 1149.23
039-neg-g0 68330 69802 67488 69144 68691 343455 25114.63 23,965    
039-vit-g0 1 118035 123832 118239 119795 119975 599876.3 44156.72 43,317    
039-vit-g0 2 139878 138467 147644 151847 144459 722295 53247.65 52,408    
039-vit-g10 1 36788 35498 35138 44517 37985 189926.3 13713.44 12,874    
039-vit-g10 2 56231 50863 49559 52777 52358 261787.5 19049.93 18,211    
039-vit-g10 3 44734 45127 51731 44204 46449 232245 16856.07 15,707    
040-blank 3413 3163 3134 3170 3220 16100 804.9379
040-vit-blank 4635 4097 4302 4624 4415 22072.5 1248.461
040-neg-g0 45408 43357 47378 44619 45191 225952.5 16388.78 15,140    
040-vit-g0 1 131032 138775 149445 136979 139058 695288.8 51242.14 50,437    
040-vit-g0 2 71006 73082 69214 68129 70358 351788.8 25733.5 24,929    
040-vit-g50 1 20073 21679 21310 19911 20743 103716.3 7311.404 6,506      
040-vit-g50 2 81698 84389 86148 82707 83736 418677.5 30700.73 29,896    
040-vit-g50 3 31445 32255 30136 34167 32001 160003.8 11491.37 10,686    
(AVG*5-
Intercept
)/ SLOPE
On 
Thread
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041-042 
 
 
 
 
 
 
 
 
 
 
average Corr Coeff Slope Intercept
12000 142939 144752 144080 147333 144776 0.999161 11.9419 3698.19
6000 76376 83254 72936 80498 78266
3000 41384 42231 42996 43007 42405
1500 22268 23210 23955 21092 22631
750 13129 11761 12351 11816 12264
375 6293 6438 7430 8311 7118
187.5 3960 4565 4603 4622 4438
0 2059 2049 2060 2050 2055
AVG*5 
041-48hr-blank 2773 2824 2859 2986 2861 14302.5 887.9918
041-48hr-24hrcontrol 20845 20921 20789 20166 20680 103401.3 8349.012 7,461      
041-48hr-g-0 1 20653 21036 22876 21782 21587 107933.8 8728.558 7,841      
041-48hr-g-0 2 24982 23972 24718 24363 24509 122543.8 9951.982 9,064      
041-48hr-g-10 1 14378 13439 14375 12928 13780 68900 5459.92 4,572      
041-48hr-g-10 2 26579 27056 26155 25894 26421 132105 10752.63 9,865      
041-48hr-g-10 3 30600 30986 30089 29865 30385 151925 12412.33 11,524    
041-48hr-g-10 4 50512 55024 54541 60889 55242 276207.5 22819.6 21,932    
042-48hr-blank 2755 2845 2819 2897 2829 14145 874.803
042-48hr-24hrcontrol 27480 25334 25284 26588 26172 130857.5 10648.16 9,773      
042-48hr-g-0 1 39123 40250 38617 38356 39087 195432.5 16055.6 15,181    
042-48hr-g-0 2 15466 16908 15795 16613 16196 80977.5 6471.275 5,596      
042-48hr-g-50 1 23159 24321 25183 23437 24025 120125 9749.438 8,875      
042-48hr-g-50 2 19670 18483 19174 18968 19074 95368.75 7676.38 6,802      
042-48hr-g-50 3 13095 12897 12590 13506 13022 65110 5142.55 4,268      
042-48hr-g-50 4 41162 40655 41872 41111 41200 206000 16940.51 16,066    
(AVG*5-
Intercept
)/ SLOPE
On 
Thread
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046-047-048 
 
 
 
 
 
 
average Corr Coeff Slope Intercept
12000 158605 165709 161320 167572 163302 0.997342 13.72127 3039.68
6000 86212 87903 91546 115178 95210
3000 48370 46461 45639 30437 42727
1500 25293 24904 24469 17565 23058
750 14243 12587 13915 9983 12682
375 7264 7722 7439 5901 7082
187.5 5436 4665 4697 4304 4776
0 1968 2727 2063 2124 2221
AVG*5 
046-48hr-blank 3081 2758 2693 2892 2856 14280 819.1891
046-48hr-g-0 44720 44714 47891 44631 45489 227445 16354.56 15,535    
046-48hr-g-10 1 52048 54785 53970 54013 53704 268520 19348.08 18,529    
046-48hr-g-10 2 48559 46648 49098 49345 48413 242062.5 17419.87 16,601    
046-48hr-g-10 2 22648 22824 22519 22554 22636 113181.3 8027.067 7,208      
048-48hr-g-50 1 22172 21482 20975 22218 21712 108558.8 7690.181 6,871      
048-48hr-g-50 2 43726 41658 41804 42491 42420 212098.8 15236.13 14,417    
047-48hr-blank 2612 2767 2662 2832 2718 13591.25 768.9934
047-48hr-24hrcontrol 66320 64820 65374 66674 65797 328985 23754.75 22,986    
047-48hr-g-0 6332 6605 6033 7135 6526 32631.25 2156.62 1,388      
047-48hr-g-10 1 22865 22018 23963 22756 22901 114502.5 8123.359 7,354      
047-48hr-g-10 2 6253 5114 5779 6843 5997 29986.25 1963.853 1,195      
047-48hr-g-10 3 11495 10139 10325 10585 10636 53180 3654.203 2,885      
(AVG*5-
Intercept
)/ SLOPE
On 
Thread
